WO2024040237A1 - Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine - Google Patents
Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine Download PDFInfo
- Publication number
- WO2024040237A1 WO2024040237A1 PCT/US2023/072499 US2023072499W WO2024040237A1 WO 2024040237 A1 WO2024040237 A1 WO 2024040237A1 US 2023072499 W US2023072499 W US 2023072499W WO 2024040237 A1 WO2024040237 A1 WO 2024040237A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- gly
- derivative
- amino acid
- side chain
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 256
- 239000000556 agonist Substances 0.000 title claims description 5
- 108060005714 orexin Proteins 0.000 title description 18
- 102000002512 Orexin Human genes 0.000 title description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 77
- 150000003839 salts Chemical class 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 57
- 208000035475 disorder Diseases 0.000 claims abstract description 44
- 239000000651 prodrug Substances 0.000 claims abstract description 33
- 229940002612 prodrug Drugs 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 20
- 208000024891 symptom Diseases 0.000 claims abstract description 15
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims abstract description 8
- 108050000742 Orexin Receptor Proteins 0.000 claims abstract description 8
- 102000008834 Orexin receptor Human genes 0.000 claims abstract description 8
- 201000003631 narcolepsy Diseases 0.000 claims abstract description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 5
- 206010002091 Anaesthesia Diseases 0.000 claims abstract description 4
- 206010010071 Coma Diseases 0.000 claims abstract description 4
- 206010019280 Heart failures Diseases 0.000 claims abstract description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 4
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 4
- 230000037005 anaesthesia Effects 0.000 claims abstract description 4
- 208000016361 genetic disease Diseases 0.000 claims abstract description 4
- 206010020765 hypersomnia Diseases 0.000 claims abstract description 3
- 230000004630 mental health Effects 0.000 claims abstract description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 1346
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 453
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 452
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 450
- -1 Ala Chemical compound 0.000 claims description 411
- 125000000539 amino acid group Chemical group 0.000 claims description 360
- 230000002209 hydrophobic effect Effects 0.000 claims description 181
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 156
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 142
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 138
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 137
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 claims description 127
- UEKYKRQIAQHOOZ-KBPBESRZSA-N Pro-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)[O-])C(=O)[C@@H]1CCC[NH2+]1 UEKYKRQIAQHOOZ-KBPBESRZSA-N 0.000 claims description 122
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 67
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 63
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims description 56
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 50
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims description 49
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 49
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 43
- 201000010099 disease Diseases 0.000 claims description 33
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 14
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 5
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims description 4
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 19
- 230000000063 preceeding effect Effects 0.000 claims 11
- 101000598921 Homo sapiens Orexin Proteins 0.000 claims 2
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 27
- 238000002360 preparation method Methods 0.000 abstract description 9
- 238000001949 anaesthesia Methods 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 description 436
- 125000004093 cyano group Chemical group *C#N 0.000 description 430
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 203
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 165
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 117
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 57
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 51
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 48
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 36
- 125000001424 substituent group Chemical group 0.000 description 26
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 24
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 23
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 23
- 125000004429 atom Chemical group 0.000 description 23
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 20
- 125000003118 aryl group Chemical group 0.000 description 20
- 125000002698 D-tryptophano group Chemical group C(=O)(O)[C@@H](CC1=CNC2=CC=CC=C12)N* 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 16
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 125000001072 heteroaryl group Chemical group 0.000 description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 15
- 239000012453 solvate Substances 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000000155 isotopic effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 206010041349 Somnolence Diseases 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 208000001573 Cataplexy Diseases 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 125000001246 bromo group Chemical group Br* 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 235000021317 phosphate Nutrition 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 7
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 7
- 150000001204 N-oxides Chemical class 0.000 description 7
- 229940127340 Orexin Receptor Agonists Drugs 0.000 description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 150000007942 carboxylates Chemical class 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
- 125000003301 D-leucyl group Chemical group N[C@@H](C(=O)*)CC(C)C 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000004442 acylamino group Chemical group 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 6
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 6
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 6
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 6
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- 125000001769 aryl amino group Chemical group 0.000 description 6
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 6
- 125000005129 aryl carbonyl group Chemical group 0.000 description 6
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 6
- 125000005110 aryl thio group Chemical group 0.000 description 6
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000004663 dialkyl amino group Chemical group 0.000 description 6
- 125000004986 diarylamino group Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 230000007958 sleep Effects 0.000 description 6
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 6
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 6
- 238000003419 tautomerization reaction Methods 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000035959 Narcolepsy type 1 Diseases 0.000 description 5
- 206010062519 Poor quality sleep Diseases 0.000 description 5
- 208000032140 Sleepiness Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 208000004461 narcolepsy 1 Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000037321 sleepiness Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010034143 Inflammasomes Proteins 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000033409 Narcolepsy type 2 Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000185 intracerebroventricular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UXZAJSZFFARTEI-YRPNKDGESA-N CS(=O)(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OC)CO[C@@H]1CC[C@@H](CC1)C1=CC=CC=C1 Chemical compound CS(=O)(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OC)CO[C@@H]1CC[C@@H](CC1)C1=CC=CC=C1 UXZAJSZFFARTEI-YRPNKDGESA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000004461 rapid eye movement Effects 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- BXJSAMKIFDDLGI-UHFFFAOYSA-N 2-(dimethylamino)-N-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]benzamide Chemical compound COc1ccc(cc1S(=O)(=O)Nc1cccc(NCCNC(=O)c2ccccc2N(C)C)c1)-c1cccc(c1)C(=O)N(C)C BXJSAMKIFDDLGI-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001423 Advanced sleep phase Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012209 Delayed sleep phase Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020928 Hypnopompic hallucination Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 201000002983 Mobius syndrome Diseases 0.000 description 1
- 208000034167 Moebius syndrome Diseases 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 125000000982 N(2)-D-asparagino group Chemical group [H]OC(=O)[C@]([H])(N([H])[*])C(C(=O)N([H])[H])([H])[H] 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000025464 Norrie disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010067493 Sleep inertia Diseases 0.000 description 1
- 208000005439 Sleep paralysis Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000009808 cranioectodermal dysplasia Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003796 lateral hypothalamic area Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 201000005439 recurrent hypersomnia Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000033914 shift work type circadian rhythm sleep disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present disclosure relates to small peptide orexin receptor agonists designed for the treatment of narcolepsy or other disorders associated with orexin insufficiency and/or excessive sleepiness.
- Narcolepsy afflicts 1 in 2000 individuals worldwide. Onset may occur during adolescence for a lifelong duration and debilitating impact on quality of life.
- Narcolepsy Type 1 (NTl) is caused by the loss of neurons in the brain which produce orexin neuropeptides. There is no known cure, and currently approved treatments are symptomatic and do not address the underlying cause of the disorder. Thus, development of pharmacotherapeutics to restore lost orexin signaling is critically important for treatment of the root cause of NTl .
- Narcolepsy Type 1 the sole population of neurons in the brain that produce orexin A and B (also known as hypocretin- 1 and 2) peptides are destroyed by an immune-mediated mechanism which causes arousal state boundary dysfunction.
- Mouse models of narcolepsy type 1 recapitulate the orexin neurodegeneration and the two cardinal symptoms observed in NTl patients, specifically excessive sleepiness and cataplexy-like events.
- Symptoms of narcolepsy type 1 and type 2 may include excessive daytime sleepiness, disturbed nighttime sleep, hypnagogic and hypnopompic hallucinations, and inappropriately timed rapid-eye- movement (REM) sleep.
- REM rapid-eye- movement
- Cataplexy is the intrusion of sudden, reversible loss of muscle tone (the atonia of REM sleep) into wakefulness in response to emotional stimuli and is pathognomonic of NTL Metabolic syndrome including insulin resistance is also observed in individuals with narcolepsy, particularly NTL
- narcolepsy type 1 The two predominant symptoms of narcolepsy type 1, excessive sleepiness and cataplexy, can be reduced by re-activation of orexin neurotransmission at 0X2R.
- Reversal of cataplexy-like events and sleep/wake fragmentation has been achieved by genetic, focal restoration of 0X2R signaling in the dorsal raphe nucleus of the pons and the tuberomammillary nucleus of the hypothalamus, respectively, in mice that otherwise lack orexin receptors in those regions.
- Intracerebroventricular (ICV) administration of orexin A (OXA) has been shown to increase time spent awake and decreases cataplexy -like behavior in orexin-neuron ablated mice.
- the selective 0X2R agonist, YNT-185 administered intraperitoneally or ICV modestly increases wakefulness in wild type (WT) and orexin liganddeficient mice, and decreases sleep-onset REM periods and cataplexy-like events in an NT1 mouse model.
- Subcutaneous administration of TAK-925 modestly increased wakefulness in WT mice, but not in OX2R-knockout mice.
- Brain penetrant and stable 0X2R agonists that are bioavailable after alternative routes of administration (including but not limited to oral, intranasal, transmucosal, and transdermal) and that bind with high affinity for potent excitation of arousal-state regulating neurons will provide an improvement to current therapeutics for patients with NT1.
- Orexin receptor agonists may also be useful in other indications marked by some degree of orexin neurodegeneration, decreased orexin levels (e.g., as measured in CSF), or decreased orexin signaling, and/or excessive daytime sleepiness, such as narcolepsy type 2, idiopathic hypersomnia, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, Prader-Willi syndrome, multiple sclerosis, depression (including atypical depression and major depressive disorder), and traumatic brain injury.
- Orexin receptor agonists may also reduce excessive sleep, sleep paralysis, sleep inertia and sleep drunkenness in disorders such as narcolepsy and idiopathic hypersomnia. Because stimulation of 0X2R promotes wakefulness in orexin-intact animals, orexin receptor agonists may treat or decrease excessive daytime sleepiness in patients (‘with normal’ or) without reduced levels of orexin, including narcolepsy type 2, idiopathic hypersomnia, sleep apnea and other underlying sleep disorders.
- orexin receptor agonists may confer wake-promoting benefits in disorders of recurrent hypersomnia, such as Klein-Levin syndrome, or inappropriately timed sleep (i.e., circadian rhythm sleep disorders), such as delayed- or advanced-sleep phase disorder, shift work disorder and jet lag disorder, and excessive sleepiness caused by a disrupted sleep cycle.
- disorders of recurrent hypersomnia such as Klein-Levin syndrome
- inappropriately timed sleep i.e., circadian rhythm sleep disorders
- circadian rhythm sleep disorders such as delayed- or advanced-sleep phase disorder, shift work disorder and jet lag disorder, and excessive sleepiness caused by a disrupted sleep cycle.
- the abnormal daytime sleepiness, sleep onset REM periods, and cataplexy-like symptoms of some rare genetic disorders could be alleviated with orexin receptor agonists.
- some rare genetic disorders e.g., ADCA-DN, Myotonic Dystrophy, Coffin-Lowry syndrome, Moebius syndrome, Norrie disease, Niemann-Pick disease type C, Smith-Magenis Syndrome (SMS), mucopolysaccharidoses (MPS) disorders, and Prader-Willi syndrome
- orexin receptor agonists include attention deficit hyperactivity disorder, cognitive dysfunction related to age, disease or medications, metabolic syndrome and obesity, depression, fatigue, osteoporosis, cardiac failure, coma, and emergence from anesthesia.
- the disclosure arises from a need to provide peptides for the modulation of orexin receptor activity in the brain, including activation of the orexin-2 receptor, with improved therapeutic potential.
- peptides with improved physicochemical, pharmacological and pharmaceutical properties to existing compounds are desirable.
- the present disclosure provides a peptide having a sequence comprising: (SEQ ID NO: 1), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent or an amino acid group comprising a hydrophobic side chain, or a derivative thereof; X 2 is absent, an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof; X 3 is absent, an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising a hydrophobic side chain, or a derivative thereof; X 4 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof; X 5 is an amino acid group comprising an electrically charged side
- X9 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X10 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X11 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof, an amino acid group comprising a hydrophobic side chain, or a derivative thereof, or an amino acid group comprising a electrically charged side chain, or a derivative thereof;
- X12 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X13 is an amino acid group comprising an electrically charged side chain, or a derivative thereof, or an amino acid group comprising a polar uncharged side chain, or a derivative thereof;
- X14 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X15 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof
- Xi6 is an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a hydrophobic side chain, or a derivative thereof; or an amino acid group comprising a polar uncharged side chain, or a derivative thereof;
- X17 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X18 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X19 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X20 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X21 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof
- X22 an amino acid group comprising a polar uncharged side chain, or a derivative thereof
- X 23 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- the present disclosure provides a peptide having a sequence comprising: (SEQ ID NO: 2), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent or an amino acid group comprising a hydrophobic side chain, or a derivative thereof; X 2 is absent, an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof; X 3 is absent, an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising a hydrophobic side chain, or a derivative thereof; X 4 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof; X 5 is an amino acid group comprising an electrically charged side chain, or
- the present disclosure provides a peptide having a sequence comprising: 3), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 1 is optionally substituted with halo, -OH, - O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl,
- the present disclosure provides a peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 4), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent, AIB, Ala, D-Ala, or Gly; X 2 is absent, D-Ser, or Leu; X 3 is absent, CycloLys, D-Ser, Gln, Phe, or Pro; X 4 is AIB, D-Ser, or Gly; X 5 is Arg, D-Ser, or PipAla; X 6 is Ala, AIB, or D-Ser; X 7 is CycloGlu, CycloLys, D-Ser,
- the present disclosure provides a peptide obtainable by, or obtained by, a method described herein.
- the present disclosure provides a pharmaceutical composition comprising the peptide disclosed herein or an isomer, pharmaceutically acceptable salt, or prodrug thereof, and a pharmaceutically acceptable diluent or carrier.
- the present disclosure provides a method of modulating orexin-2 receptor activity, comprising contacting a cell with an effective amount of the peptide disclosed herein.
- the present disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the peptide or pharmaceutical composition disclosed herein.
- the present disclosure provides a peptide or pharmaceutical composition disclosed herein for use in modulating orexin-2 receptor activity; optionally, the activity is in vitro or in vivo. [0016] In some aspects, the present disclosure provides a peptide or pharmaceutical composition disclosed herein for use in treating or preventing a disease or disorder. [0017] In some aspects, the present disclosure provides a use of the peptide disclosed herein in the manufacture of a medicament for modulating orexin-2 receptor activity. [0018] In some aspects, the present disclosure provides a use of the peptide disclosed herein in the manufacture of a medicament for treating or preventing a disease or disorder.
- the present disclosure provides a method, use, or peptide or pharmaceutical composition for use of the peptide disclosed herein in combination with one or more additional therapy.
- all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the specification, the singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present specification, including definitions, will control.
- the present disclosure also relates to processes for the preparation of these peptides, to pharmaceutical compositions comprising them and to their use in the treatment of disorders in which the orexin receptor is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.
- disorders in which the orexin receptor is implicated such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.
- the disclosure may be interpreted as excluding the non-operable embodiments caused by certain combinations of the options.
- various options for variables X, L, and Y are described herein, the disclosure may be interpreted as excluding structures for non-operable peptides caused by certain combinations of variables X, L, and Y (e.g., when each of X, L, and Y is -O-).
- alkyl As used herein, “alkyl”, “C 1 , C 2 , C 3 , C 4 , C 5 or C 6 alkyl” or “C 1 -C 6 alkyl” is intended to include C 1 , C 2 , C 3 , C 4 , C 5 or C 6 straight chain (linear) saturated aliphatic hydrocarbon groups and C 3 , C 4 , C 5 or C 6 branched saturated aliphatic hydrocarbon groups.
- C 1 -C 6 alkyl is intends to include C 1 , C 2 , C 3 , C 4 , C 5 and C 6 alkyl groups.
- alkyl examples include, moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, or n-hexyl.
- a straight chain or branched alkyl has six or fewer carbon atoms (e.g., C 1 -C 6 for straight chain, C3-C6 for branched chain), and in another embodiment, a straight chain or branched alkyl has four or fewer carbon atoms.
- optionally substituted alkyl refers to unsubstituted alkyl or alkyl having designated substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone.
- substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino), acylamino (including alky
- alkenyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
- alkenyl includes straight chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), and branched alkenyl groups.
- a straight chain or branched alkenyl group has six or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
- C 2 -C 6 includes alkenyl groups containing two to six carbon atoms.
- C 3 -C 6 includes alkenyl groups containing three to six carbon atoms.
- optionally substituted alkenyl refers to unsubstituted alkenyl or alkenyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
- substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sul
- alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
- alkynyl includes straight chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), and branched alkynyl groups.
- a straight chain or branched alkynyl group has six or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
- C 2 -C 6 includes alkynyl groups containing two to six carbon atoms.
- C 3 - C 6 includes alkynyl groups containing three to six carbon atoms.
- C 2 -C 6 alkenylene linker or “C 2 -C 6 alkynylene linker” is intended to include C 2 , C 3 , C 4 , C 5 or C 6 chain (linear or branched) divalent unsaturated aliphatic hydrocarbon groups.
- C 2 - C 6 alkenylene linker is intended to include C 2 , C 3 , C 4 , C 5 and C 6 alkenylene linker groups.
- optionalally substituted alkynyl refers to unsubstituted alkynyl or alkynyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
- substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sul
- optionally substituted moieties include both the unsubstituted moieties and the moieties having one or more of the designated substituents.
- substituted heterocycloalkyl includes those substituted with one or more alkyl groups, such as 2,2,6,6-tetramethyl- piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.
- cycloalkyl refers to a saturated or partially unsaturated hydrocarbon monocyclic or polycyclic (e.g., fused, bridged, or spiro rings) system having 3 to 30 carbon atoms (e.g., C 3 -C 12 , C 3 -C 10 , or C 3 -C 8 ).
- cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthalenyl, and adamantyl.
- cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthalenyl, and adamantyl.
- polycyclic cycloalkyl only one of the rings in the cycloalkyl needs to be non- aromatic.
- heterocycloalkyl refers to a saturated or partially unsaturated 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged, or spiro rings), or 11-14 membered tricyclic ring system (fused, bridged, or spiro rings) having one or more heteroatoms (such as O, N, S, P, or Se), e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or e.g. 1 ⁇ , 2, 3, 4, 5, or 6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur, unless specified otherwise.
- heteroatoms such as O, N, S, P, or Se
- heterocycloalkyl groups include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, 1,2,3,6- tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, tetrahydrothiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-
- aryl includes groups with aromaticity, including “conjugated,” or multicyclic systems with one or more aromatic rings and do not contain any heteroatom in the ring structure.
- aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like.
- heteroaryl is intended to include a stable 5-, 6-, or 7- membered monocyclic or 7-, 8-, 9-, 10-, 11- or 12-membered bicyclic aromatic heterocyclic ring which consists of carbon atoms and one or more heteroatoms, e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or e.g. ⁇ 1, 2, 3, 4, 5, or 6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur.
- the nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or other substituents, as defined).
- heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.
- Heteroaryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).
- the heteroaryl is thiophenyl or benzothiophenyl.
- the heteroaryl is thiophenyl.
- the heteroaryl benzothiophenyl.
- aryl and heteroaryl include multicyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
- the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring can be substituted at one or more ring positions (e.g., the ring-forming carbon or heteroatom such as N) with such substituents as described above, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino
- Aryl and heteroaryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g., tetralin, methylenedioxyphenyl such as benzo[d][1,3]dioxole-5-yl).
- substituted means that any one or more hydrogen atoms on the designated atom is replaced with a selection from the indicated groups, provided that the designated atom’s normal valency is not exceeded, and that the substitution results in a stable peptide.
- 2 hydrogen atoms on the atom are replaced.
- Keto substituents are not present on aromatic moieties.
- “Stable peptide” and “stable structure” are meant to indicate a peptide that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. [0039] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom in the ring.
- hydroxy or “hydroxyl” includes groups with an -OH or -O- .
- halo or “halogen” refers to fluoro, chloro, bromo and iodo.
- haloalkyl or “haloalkoxyl” refers to an alkyl or alkoxyl substituted with one or more halogen atoms.
- optionally substituted haloalkyl refers to unsubstituted haloalkyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
- substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sul
- alkoxy or “alkoxyl” includes substituted and unsubstituted alkyl, alkenyl and alkynyl groups covalently linked to an oxygen atom.
- alkoxy groups or alkoxyl radicals include, but are not limited to, methoxy, ethoxy, isopropyloxy, propoxy, butoxy and pentoxy groups.
- substituted alkoxy groups include halogenated alkoxy groups.
- the alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, s
- halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy and trichloromethoxy.
- hArg(Et) 2 refers t .
- hArg refers t .
- hLys refers t .
- 2-AOC refers t
- 2-AHP refers t
- NVA refers .
- the term “Phe(3-Br)” refers t [0053] As used herein, the term “NLE” refers t [0054] As used herein, the term “alpha-Me-NLE” refers t [0055] As used herein, the term “Phg” refers t [0056] As used herein, the term “Phg(4-OH)” refers t [0057] As used herein, the term “Nag(1)” refers t [0058] As used herein, the term “Phg(4-OMe)” refers t [0059] As used herein, the term “Phg(3-OH)” refers t OH HN OH [0060] As used herein, the term “Hyp(4-OH)” refers to O .
- N-Me-Asn refers t
- N-Phenethyl-Gly refers t
- N(naphthalen-2-yl-ethyl)-Gly refers t
- N(naphthalen-1-yl-ethyl)-Gly refers t
- N-(4-OMe-Phenethyl)-Gly refers t
- N-(3-EtNH 2 -Phenethyl)-Gly refers t .
- the term “AIB” refers to .
- the term “PipALA” refers t
- “CycloLys” followed later in the sequence by “CycloGlu” refers to two residues connected by an amide bond, for example, .
- polar uncharged side chain refers to a hydrophilic moiety that can hydrogen bond with another molecule at physiological pH.
- electrically charged side chain refers to a charged moiety (e.g., negative or positive) at physiological pH.
- polar charged side chain refers to a charged moiety that can hydrogen bond with another molecule at physiological pH.
- hydrophobic side chain refers to a moiety with a small dipole moments that may be repelled from water.
- amino acid substitutions can occur between amino acids with similar properties (i.e. classifications). For example, an amino acid classified as “hydrophobic” may be substituted with a different amino acid classified as “hydrophobic” when the hydrophobic property is desired at a position in an amino acid sequence.
- amino acid substitutions such as charge classification (e.g. neutral, positive, or negative), hydrophobic, hydrophilic, polar, non-polar, acidic, basic, aliphatic, and aromatic amino acids. It is understood that amino acids can have one or more categorization. For example, an amino acid may be “polar charged” or “polar uncharged.” Substitution of one amino acid for another of the same classification is contemplated for the amino acid sequences described herein.
- amino acid categorizations are summarized below: [0075] As used herein, the expressions “one or more of A, B, or C,” “one or more A, B, or C,” “one or more of A, B, and C,” “one or more A, B, and C,” “selected from the group consisting of A, B, and C”, “selected from A, B, and C”, and the like are used interchangeably and all refer to a selection from a group consisting of A, B, and/or C, i.e., one or more As, one or more Bs, one or more Cs, or any combination thereof, unless indicated otherwise.
- compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components. Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps. Further, it should be understood that the order of steps order for performing certain actions is immaterial so long as the invention remains operable.
- peptides of the present disclosure can be prepared in a variety of ways using commercially available starting materials, peptides known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or which will be apparent to the skilled artisan in light of the teachings herein.
- Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B., March, J., March’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5 th edition, John Wiley & Sons: New York, 2001; Greene, T.W., Wuts, P.G. M., Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M.
- any description of a method of treatment or prevention includes use of the peptides to provide such treatment or prevention as is described herein. It is to be further understood, unless otherwise stated, any description of a method of treatment or prevention includes use of the peptides to prepare a medicament to treat or prevent such condition.
- the treatment or prevention includes treatment or prevention of human or non-human animals including rodents and other disease models.
- any description of a method of treatment includes use of the peptides to provide such treatment as is described herein. It is to be further understood, unless otherwise stated, any description of a method of treatment includes use of the peptides to prepare a medicament to treat such condition.
- the treatment includes treatment of human or non-human animals including rodents and other disease models.
- the term “subject” is interchangeable with the term “subject in need thereof”, both of which refer to a subject having a disease or having an increased risk of developing the disease. A “subject” includes a mammal.
- the mammal can be e.g., a human or appropriate non-human mammal, such as primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or a pig.
- the subject can also be a bird or fowl.
- the mammal is a human.
- a subject in need thereof can be one who has been previously diagnosed or identified as having a disease or disorder disclosed herein.
- a subject in need thereof can also be one who is suffering from a disease or disorder disclosed herein.
- a subject in need thereof can be one who has an increased risk of developing such disease or disorder relative to the population at large (i.e., a subject who is predisposed to developing such disorder relative to the population at large).
- a subject in need thereof can have a refractory or resistant a disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment).
- the subject may be resistant at start of treatment or may become resistant during treatment.
- the subject in need thereof received and failed all known effective therapies for a disease or disorder disclosed herein.
- the subject in need thereof received at least one prior therapy.
- the term “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a peptide of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder.
- the term “treat” can also include treatment of a cell in vitro or an animal model. It is to be appreciated that references to “treating” or “treatment” include the alleviation of established symptoms of a condition.
- Treating” or “treatment” of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
- a peptide of the present disclosure can or may also be used to prevent a relevant disease, condition or disorder, or used to identify suitable candidates for such purposes.
- the term “preventing,” “prevent,” or “protecting against” describes reducing or eliminating the onset of the symptoms or complications of such disease, condition or disorder.
- one skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc.
- the present disclosure also provides pharmaceutical compositions comprising any peptide described herein in combination with at least one pharmaceutically acceptable excipient or carrier.
- pharmaceutical composition is a formulation containing the peptides of the present disclosure in a form suitable for administration to a subject.
- the pharmaceutical composition is in bulk or in unit dosage form.
- the unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler or a vial.
- the quantity of active ingredient (e.g., a formulation of the disclosed peptide or salt, hydrate, solvate or isomer thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved.
- active ingredient e.g., a formulation of the disclosed peptide or salt, hydrate, solvate or isomer thereof
- the dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalational, buccal, sublingual, intrapleural, intrathecal, intranasal, and the like.
- Dosage forms for the topical or transdermal administration of a peptide of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active peptide is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.
- the term “pharmaceutically acceptable” refers to those peptides, anions, cations, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable excipient means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use.
- a “pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., ingestion), inhalation, transdermal (topical), and transmucosal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- a peptide or pharmaceutical composition of the disclosure can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment.
- a peptide of the disclosure may be injected into the blood stream or body cavities or taken orally or applied through the skin with patches.
- the dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects.
- the state of the disease condition e.g., a disease or disorder disclosed herein
- the health of the patient should preferably be closely monitored during and for a reasonable period after treatment.
- the term “therapeutically effective amount”, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect.
- the effect can be detected by any assay method known in the art.
- the precise effective amount for a subject will depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration.
- Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
- the term “therapeutically effective amount” refers to an amount of a pharmaceutical agent to treat or ameliorate an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect.
- the effect can be detected by any assay method known in the art.
- the precise effective amount for a subject will depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration.
- Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
- the therapeutically effective amount can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50 (the dose therapeutically effective in 50 % of the population) and LD 50 (the dose lethal to 50 % of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD 50 /ED 50 .
- Pharmaceutical compositions that exhibit large therapeutic indices are preferred.
- the dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. [0097] Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect.
- compositions containing active peptides of the present disclosure may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilising processes.
- compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of the active peptides into preparations that can be used pharmaceutically.
- the appropriate formulation is dependent upon the route of administration chosen.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor EL ⁇ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol and sorbitol, and sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active peptide in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilisation.
- dispersions are prepared by incorporating the active peptide into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
- methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier.
- compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the peptide in the fluid carrier is applied orally and swished and expectorated or swallowed.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or peptides of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the peptides are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebuliser.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebuliser.
- the peptides are delivered in solution or solid formulation. In some embodiments, the peptides are delivered in solution as a mist, a drip, or a swab. In some embodiments, the peptides are delivered as a powder. In some embodiments, the peptide is included in a kit which further includes an intranasal applicator.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active peptides are formulated into ointments, salves, gels, or creams as generally known in the art.
- the active peptides can be prepared with pharmaceutically acceptable carriers that will protect the peptide against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No.4,522,811. [0106] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active peptide calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active peptide and the particular therapeutic effect to be achieved.
- the dosages of the pharmaceutical compositions used in accordance with the disclosure vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage.
- the dose should be sufficient to result in slowing, and preferably regressing, the symptoms of the disease or disorder disclosed herein and also preferably causing complete regression of the disease or disorder.
- Dosages can range from about 0.01 mg/kg per day to about 5000 mg/kg per day.
- An effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer. Improvement in survival and growth indicates regression.
- the term “dosage effective manner” refers to amount of an active peptide to produce the desired biological effect in a subject or cell.
- the term “pharmaceutically acceptable salts” refer to derivatives of the peptides of the present disclosure wherein the parent peptide is modified by making acid or base salts thereof.
- pharmaceutically acceptable salts include, but are not limited to, mineral organic acid salts of basic residues such as amines, alkali organic salts of acidic residues such as carboxylic acids, and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent peptide formed, for example, from non-toxic inorganic organic acids.
- such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, 1,2-ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic,
- the pharmaceutically acceptable salt is a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a diethylamine salt, a choline salt, a meglumine salt, a benzathine salt, a tromethamine salt, an ammonia salt, an arginine salt, or a lysine salt.
- compositions include hexanoic acid, cyclopentane propionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3- phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, muconic acid, and the like.
- the present disclosure also encompasses salts formed when an acidic proton present in the parent peptide either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
- a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion
- an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
- the ratio of the peptide to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, e.g., 3:1, 2:1, 1:2, or 1:3.
- peptides, or pharmaceutically acceptable salts thereof are administered orally, nasally, transdermally, pulmonary, inhalationally, buccally, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally and parenterally. In some embodiments, the peptide is administered orally.
- One skilled in the art will recognise the advantages of certain routes of administration.
- the dosage regimen utilising the peptides is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular peptide or salt thereof employed.
- An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.
- An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to counter or arrest the progress of the condition.
- the peptides described herein, and the pharmaceutically acceptable salts thereof are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent.
- suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous organic solutions.
- the peptides will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein.
- the present disclosure provides a peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 1), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent or an amino acid group comprising a hydrophobic side chain, or a derivative thereof; X 2 is absent, an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof; X 3 is absent, an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising
- the present disclosure provides a peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 2), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent or an amino acid group comprising a hydrophobic side chain, or a derivative thereof; X 2 is absent, an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof; X 3 is absent, an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising a hydrophobic side chain
- the present disclosure provides a peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 3), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl
- the present disclosure provides a peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 4), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent, AIB, Ala, D-Ala, or Gly; X 2 is absent, D-Ser, or Leu; X 3 is absent, CycloLys, D-Ser, Gln, Phe, or Pro; X 4 is AIB, D-Ser, or Gly; X 5 is Arg, D-Ser, or PipAla; X 6 is Ala, AIB, or D-Ser; X 7 is CycloGlu, CycloLys, D-Ser,
- variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 , X 20 , X 21 , X 22 , or X 23 can each be, where applicable, selected from the groups described herein, and any group described herein for any of variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 ,
- X 1 is absent or an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0127] In some embodiments, X 1 is absent. In some embodiments, X 1 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0128] In some embodiments, X 1 is an amino acid group comprising a hydrophobic side chain. [0129] In some embodiments, X 1 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 1 is absent, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 1 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 1 is AIB.
- X 1 is Ala.
- X 1 is D-Ala.
- X 1 is PipAla.
- X 1 is Phg. In some embodiments, X 1 is Phg(4-OH). In some embodiments, X 1 is N-Phenethyl-Gly. In some embodiments, X 1 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 1 is N-(4- OMe-Phenethyl)-Gly. In some embodiments, X 1 is Gly. In some embodiments, X 1 is Val. In some embodiments, X 1 is Ile. In some embodiments, X 1 is Leu. In some embodiments, X 1 is D-Leu. In some embodiments, X 1 is Met.
- X 1 is Phe. In some embodiments, X 1 is hPhe. In some embodiments, X 1 is Pro. In some embodiments, X 1 is Tyr. In some embodiments, X 1 is Trp. In some embodiments, X 1 is D-Trp. [0135] In some embodiments, X 1 is Ala, D-Ala, or an Ala derivative. [0136] In some embodiments, X 1 is Ala, D-Ala, or PipAla. [0137] In some embodiments, X 1 is Gly or a Gly derivative.
- X 1 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 1 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 1 is Phg, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Phg, wherein the phenyl of X 1 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Phg(4-OH), wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Phg(4-OH), wherein the phenyl of X 1 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is N-Phenethyl-Gly, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is N-Phenethyl-Gly, wherein the phenyl of X 1 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 1 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 1 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Phe, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Phe, wherein the phenyl of X 1 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is hPhe, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is hPhe, wherein the phenyl of X 1 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Trp, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is Trp, wherein the phenyl of X 1 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is D-Trp, wherein the phenyl of X 1 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is D-Trp, wherein the phenyl of X 1 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 1 is absent, AIB, Ala, D-Ala, Gly, Trp, or D-Trp.
- X 1 is absent, AIB, Ala, D-Ala, or Gly.
- X 2 is absent, an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof.
- X 2 is absent or an amino acid group comprising a polar uncharged side chain, or derivative thereof.
- X 2 is absent or an amino acid group comprising a hydrophobic side chain, or derivative thereof.
- X 2 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 2 is an amino acid group comprising a polar uncharged side chain.
- X 2 is a derivative of an amino acid group comprising a polar uncharged side chain.
- X 2 is an amino acid group comprising a hydrophobic side chain, or derivative thereof.
- X 2 is an amino acid group comprising a hydrophobic side chain.
- X 2 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 2 is absent, D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4- OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl
- X 2 is D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 2 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 2 is D-Ser.
- X 2 is Ser.
- X 2 is AIB.
- X 2 is Ala.
- X 2 is D-Ala. In some embodiments, X 2 is PipAla. In some embodiments, X 2 is Phg. In some embodiments, X 2 is Phg(4-OH). In some embodiments, X 2 is N-Phenethyl-Gly. In some embodiments, X 2 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 2 is N-(4-OMe- Phenethyl)-Gly. In some embodiments, X 2 is Gly. In some embodiments, X 2 is Val. In some embodiments, X 2 is Ile. In some embodiments, X 2 is Leu.
- X 2 is D-Leu. In some embodiments, X 2 is Met. In some embodiments, X 2 is Phe. In some embodiments, X 2 is hPhe. In some embodiments, X 2 is Pro. In some embodiments, X 2 is Tyr. In some embodiments, X 2 is Trp. In some embodiments, X 2 is D-Trp. [0175] In some embodiments, X 2 is Ala, D-Ala, or an Ala derivative. [0176] In some embodiments, X 2 is Gly or a Gly derivative.
- X 2 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 2 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly. [0180] In some embodiments, X 2 is a Gly derivative.
- X 2 is Phg, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is Phg, wherein the phenyl of X 2 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is Phg(4-OH), wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is N-Phenethyl-Gly, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is N-Phenethyl-Gly, wherein the phenyl of X 2 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 2 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 2 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is Phe, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is Phe, wherein the phenyl of X 2 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is hPhe, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is hPhe, wherein the phenyl of X 2 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is Trp, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is Trp, wherein the phenyl of X 2 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is D-Trp, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is D-Trp, wherein the phenyl of X 2 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 2 is absent, D-Ser, Leu, Trp, or D-Trp.
- X 2 is absent, D-Ser, or Leu.
- X 3 is absent, an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0201] In some embodiments, X 3 is absent. [0202] In some embodiments, X 3 is an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 3 is an amino acid group comprising an electrically charged side chain, or a derivative thereof. [0204] In some embodiments, X 3 is an amino acid group comprising an electrically charged side chain. [0205] In some embodiments, X 3 is a derivative of an amino acid group comprising an electrically charged side chain. [0206] In some embodiments, X 3 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof. [0207] In some embodiments, X 3 is an amino acid group comprising a polar uncharged side chain. [0208] In some embodiments, X 3 is a derivative of an amino acid group comprising a polar uncharged side chain.
- X 3 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0210] In some embodiments, X 3 is an amino acid group comprising a hydrophobic side chain. [0211] In some embodiments, X 3 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 3 is absent, CycloLys, D-Ser, Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1
- X 3 is CycloLys, D-Ser, Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)- Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), - CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -
- X 3 is CycloLys, D-Ser, Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)- Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 2 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , - NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6
- X 3 is CycloLys, D-Ser, Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)- Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp. [0216] In some embodiments, X 3 is CycloLys.
- X 3 is D-Ser. In some embodiments, X 3 is Asn, D-Asn, N-Me-Asn, Ser, Thr, or Gln. [0217] In some embodiments, X 3 is Asn, D-Asn, or an Asn derivative. [0218] In some embodiments, X 3 is Asn or D-Asn. [0219] In some embodiments, X 3 is an Asn derivative. [0220] In some embodiments, X 3 is Asn. In some embodiments, X 3 is D-Asn. In some embodiments, X 3 is N-Me-Asn. In some embodiments, X 3 is Ser. In some embodiments, X 3 is Thr.
- X 3 is Gln.
- X 3 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 3 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 3 is AIB.
- X 3 is Ala.
- X 3 is D-Ala.
- X 3 is PipAla.
- X 3 is Phg. In some embodiments, X 3 is Phg(4-OH). In some embodiments, X 3 is N-Phenethyl-Gly. In some embodiments, X 3 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 3 is N-(4- OMe-Phenethyl)-Gly. In some embodiments, X 3 is Gly. In some embodiments, X 3 is Val. In some embodiments, X 3 is Ile. In some embodiments, X 3 is Leu. In some embodiments, X 3 is D-Leu. In some embodiments, X 3 is Met.
- X 3 is Phe. In some embodiments, X 3 is hPhe. In some embodiments, X 3 is Pro. In some embodiments, X 3 is Tyr. In some embodiments, X 3 is Trp. In some embodiments, X 3 is D-Trp. [0224] In some embodiments, X 3 is Ala, D-Ala, or an Ala derivative. [0225] In some embodiments, X 3 is Gly or a Gly derivative.
- X 3 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 3 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 3 is Phg, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Phg, wherein the phenyl of X 3 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Phg(4-OH), wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Phg(4-OH), wherein the phenyl of X 3 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is N-Phenethyl-Gly, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is N-Phenethyl-Gly, wherein the phenyl of X 3 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 3 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 3 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Phe, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Phe, wherein the phenyl of X 3 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is hPhe, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is hPhe, wherein the phenyl of X 3 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Trp, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is Trp, wherein the phenyl of X 3 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is D-Trp, wherein the phenyl of X 3 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is D-Trp, wherein the phenyl of X 3 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 3 is absent, CycloLys, D-Ser, Gln, Phe, or Pro.
- X 4 is an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof. [0249] In some embodiments, X 4 is an amino acid group comprising a polar uncharged side chain, or derivative thereof. [0250] In some embodiments, X 4 is an amino acid group comprising a polar uncharged side chain. [0251] In some embodiments, X 4 is a derivative of an amino acid group comprising a polar uncharged side chain. [0252] In some embodiments, X 4 is an amino acid group comprising a hydrophobic side chain, or derivative thereof.
- X 4 is an amino acid group comprising a hydrophobic side chain.
- X 4 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 4 is D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C
- X 4 is D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 4 is D-Ser.
- X 4 is Ser.
- X 4 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 4 is AIB.
- X 4 is Ala.
- X 4 is D-Ala.
- X 4 is PipAla.
- X 2 is Phg.
- X 4 is Phg(4-OH).
- X 4 is N-Phenethyl-Gly.
- X 4 is N(naphtha-2-yl-ethyl)-Gly.
- X 4 is N-(4- OMe-Phenethyl)-Gly.
- X 4 is Gly.
- X 4 is Val.
- X 4 is Ile.
- X 4 is Leu.
- X 4 is D-Leu.
- X 4 is Met.
- X 4 is Phe. In some embodiments, X 4 is hPhe. In some embodiments, X 4 is Pro. In some embodiments, X 4 is Tyr. In some embodiments, X 4 is Trp. In some embodiments, X 4 is D-Trp. [0263] In some embodiments, X 4 is Ala, D-Ala, or an Ala derivative. [0264] In some embodiments, X 4 is Gly or a Gly derivative.
- X 4 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 4 is Phg, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Phg, wherein the phenyl of X 4 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Phg(4-OH), wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Phg(4-OH), wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is N-Phenethyl-Gly, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is N-Phenethyl-Gly, wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Phe, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Phe, wherein the phenyl of X 4 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is hPhe, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is hPhe, wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Trp, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is Trp, wherein the phenyl of X 4 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is D-Trp, wherein the phenyl of X 4 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is D-Trp, wherein the phenyl of X 4 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 4 is AIB, D-Ser, or Gly.
- X 5 is an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 5 is an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 5 is an amino acid group comprising an electrically charged side chain, or a derivative thereof.
- X 5 is an amino acid group comprising an electrically charged side chain.
- X 5 is a derivative of an amino acid group comprising an electrically charged side chain.
- X 5 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 5 is an amino acid group comprising a polar uncharged side chain.
- X 5 is a derivative of an amino acid group comprising a polar uncharged side chain.
- X 5 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 5 is an amino acid group comprising a hydrophobic side chain.
- X 5 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 5 is D-Ser, Ser, Arg, hArg, D-hArg, hArg(Et) 2 , Asp, Glu, His, Hyp(4-OH), Lys, hLys, Lys-palm, AIB, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha- 2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Ala, PipAla, D-Ala, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -
- X 5 is D-Ser. In some embodiments, X 5 is Ser. [0300] In some embodiments, X 5 is Arg, hArg, D-hArg, hArg(Et) 2 , Asp, Glu, His, Lys, hLys, or Lys-palm. [0301] In some embodiments, X 5 is Arg, hArg, D-hArg, or hArg(Et) 2 . [0302] In some embodiments, X 5 is Arg. [0303] In some embodiments, X 5 is Arg derivative. [0304] In some embodiments, X 5 is hArg, D-hArg, or hArg(Et) 2 .
- X 5 is hArg. In some embodiments, X 5 is D-hArg. In some embodiments, X 5 is hArg(Et) 2 . [0306] In some embodiments, X 5 is Asp. In some embodiments, X 5 is Glu. In some embodiments, X 5 is His. [0307] In some embodiments, X 5 is Lys, hLys, or Lys-palm. [0308] In some embodiments, X 5 is Lys. [0309] In some embodiments, X 5 is hLys. In some embodiments, X 5 is Lys-palm.
- X 5 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is AIB, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 5 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), - CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 5 is AIB.
- X 5 is Ala.
- X 5 is D-Ala.
- X 5 is PipAla.
- X 5 is Phg. In some embodiments, X 5 is Phg(4-OH). In some embodiments, X 5 is N-Phenethyl-Gly. In some embodiments, X 5 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 5 is N-(4- OMe-Phenethyl)-Gly. In some embodiments, X 5 is Gly. In some embodiments, X 5 is Val. In some embodiments, X 5 is Ile. In some embodiments, X 5 is Leu. In some embodiments, X 5 is D-Leu. In some embodiments, X 5 is Met.
- X 5 is Phe. In some embodiments, X 5 is hPhe. In some embodiments, X 5 is Pro. In some embodiments, X 5 is Tyr. In some embodiments, X 5 is Trp. In some embodiments, X 5 is D-Trp. [0314] In some embodiments, X 5 is Gly or a Gly derivative.
- X 5 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 5 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 5 is Phg, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Phg, wherein the phenyl of X 5 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Phg(4-OH), wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Phg(4-OH), wherein the phenyl of X 5 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is N-Phenethyl-Gly, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is N-Phenethyl-Gly, wherein the phenyl of X 5 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 5 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 5 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Phe, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Phe, wherein the phenyl of X 5 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is hPhe, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is hPhe, wherein the phenyl of X 5 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Trp, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Trp, wherein the phenyl of X 5 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is D-Trp, wherein the phenyl of X 5 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is D-Trp, wherein the phenyl of X 5 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 5 is Arg, D-Ser, or PipAla.
- X 6 is an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof. [0338] In some embodiments, X 6 is an amino acid group comprising a polar uncharged side chain, or derivative thereof. [0339] In some embodiments, X 6 is an amino acid group comprising a polar uncharged side chain. [0340] In some embodiments, X 6 is a derivative of an amino acid group comprising a polar uncharged side chain. [0341] In some embodiments, X 6 is an amino acid group comprising a hydrophobic side chain, or derivative thereof.
- X 6 is an amino acid group comprising a hydrophobic side chain. [0343] In some embodiments, X 6 is a derivative of an amino acid group comprising a hydrophobic side chain. [0344] In some embodiments, X 6 is absent, D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl),
- X 6 is D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is D-Ser, Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is D-Ser, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 6 is D-Ser.
- X 6 is Ser.
- X 6 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 6 is AIB.
- X 6 is Ala.
- X 6 is D-Ala.
- X 6 is PipAla.
- X 2 is Phg.
- X 6 is Phg(4-OH).
- X 6 is N-Phenethyl-Gly.
- X 6 is N(naphtha-2-yl-ethyl)-Gly.
- X 6 is N-(4- OMe-Phenethyl)-Gly.
- X 6 is Gly.
- X 6 is Val.
- X 6 is Ile.
- X 6 is Leu.
- X 6 is D-Leu.
- X 6 is Met.
- X 6 is Phe. In some embodiments, X 6 is hPhe. In some embodiments, X 6 is Pro. In some embodiments, X 6 is Tyr. In some embodiments, X 6 is Trp. In some embodiments, X 6 is D-Trp. [0353] In some embodiments, X 6 is Gly or a Gly derivative.
- X 6 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 6 is Phg, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Phg, wherein the phenyl of X 6 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Phg(4-OH), wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Phg(4-OH), wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is N-Phenethyl-Gly, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is N-Phenethyl-Gly, wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Phe, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Phe, wherein the phenyl of X 6 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is hPhe, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is hPhe, wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Trp, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Trp, wherein the phenyl of X 6 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is D-Trp, wherein the phenyl of X 6 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is D-Trp, wherein the phenyl of X 6 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 6 is Ala, AIB, or D-Ser.
- X 7 is an amino acid group comprising an electrically charged side group, or a derivative thereof, or an amino acid group comprising a polar uncharged side chain, or a derivative thereof. [0377] In some embodiments, X 7 is an amino acid group comprising an electrically charged side group, or a derivative thereof. [0378] In some embodiments, X 7 is an amino acid group comprising an electrically charged side group. [0379] In some embodiments, X 7 is a derivative of an amino acid group comprising an electrically charged side group. [0380] In some embodiments, X 7 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 7 is an amino acid group comprising a polar uncharged side chain. [0382] In some embodiments, X 7 is a derivative of an amino acid group comprising a polar uncharged side chain. [0383] In some embodiments, X 7 is CycloGlu, CycloLys, D-Ser, Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe- Phenethyl)-Gly, Gly, AIB, Ala, PipAla, D-Ala, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 7 is optionally substituted with hal
- X 7 is CycloGlu or CycloLys. [0385] In some embodiments, X 7 is CycloGlu. [0386] In some embodiments, X 7 is CycloLys. [0387] In some embodiments, X 7 is D-Ser. In some embodiments, X 7 is Ser. [0388] In some embodiments, X 7 is Arg, hArg, D-hArg, hArg(Et) 2 , Asp, Glu, His, Lys, hLys, or Lys-palm. [0389] In some embodiments, X 7 is Arg or an Arg derivative.
- X 7 is Arg, hArg, D-hArg, or hArg(Et) 2 .
- X 7 is Arg.
- X 7 is Arg derivative.
- X 7 is hArg.
- X 7 is D-hArg.
- X 7 is hArg(Et) 2 .
- X 7 is Asp.
- X 7 is Glu.
- X 7 is His.
- X 7 is Lys or a Lys derivative.
- X 7 is Lys, hLys, or Lys-palm. [0396] In some embodiments, X 7 is Lys. In some embodiments, X 7 is hLys. In some embodiments, X 7 is Lys-palm. [0397] In some embodiments, X 7 is Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln. [0398] In some embodiments, X 7 is Asn, D-Asn, or an Asn derivative. [0399] In some embodiments, X 7 is Asn or D-Asn. [0400] In some embodiments, X 7 is Asn.
- X 7 is D-Asn. [0401] In some embodiments, X 7 is an Asn derivative. [0402] In some embodiments, X 7 is N-Me-Asn. [0403] In some embodiments, X 7 is Thr. In some embodiments, X 7 is Gln.
- X 7 is Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 7 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 - C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 7 is Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 7 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 7 is Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 7 is CycloGlu, CycloLys, D-Ser, or Gln.
- X 8 is an amino acid group comprising an electrically charged side chain, a derivative thereof, or an amino acid group comprising a hydrophobic side chain, or a derivative thereof, or an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 8 is an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 8 is an amino acid group comprising an electrically charged side chain, or a derivative thereof.
- X 8 is an amino acid group comprising an electrically charged side chain.
- X 8 is a derivative of an amino acid group comprising an electrically charged side chain. [0413] In some embodiments, X 8 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof. [0414] In some embodiments, X 8 is an amino acid group comprising a polar uncharged side chain. [0415] In some embodiments, X 8 is a derivative of an amino acid group comprising a polar uncharged side chain. [0416] In some embodiments, X 8 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0417] In some embodiments, X 8 is an amino acid group comprising a hydrophobic side chain.
- X 8 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 8 is Arg, hArg, D-hArg, hArg(Et) 2 , Asp, Glu, His, Hyp(4- OH), Lys, hLys, Lys-palm, Asn, D-Asn, N-Me-Asn, Ser, D-Ser, Thr, Gln, AIB, Ala, PipAla, D-Ala, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe- Phenethyl)-Gly, Gly, Val, Ile, Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 8 is
- X 8 is Arg, hArg, D-hArg, hArg(Et) 2 , Asp, Glu, His, Hyp(4- OH), Lys, hLys, or Lys-palm. [0421] In some embodiments, X 8 is Arg or an Arg derivative. [0422] In some embodiments, X 8 is Arg, hArg, D-hArg, or hArg(Et) 2 . [0423] In some embodiments, X 8 is Arg. In some embodiments, X 8 is hArg. In some embodiments, X 8 is D-hArg. In some embodiments, X 8 is hArg(Et)2.
- X 8 is Asp. In some embodiments, X 8 is Glu. In some embodiments, X 8 is His. In some embodiments, X 8 is Lys or a Lys derivative. In some embodiments, X 8 is Lys. In some embodiments, X 8 is hLys. In some embodiments, X 8 is Lys-palm. [0424] In some embodiments, X 8 is Asn, D-Asn, N-Me-Asn, Ser, Thr, or Gln. [0425] In some embodiments, X 8 is Asn. In some embodiments, X 8 is D-Asn. In some embodiments, X 8 is N-Me-Asn.
- X 8 is Ser. In some embodiments, X 8 is D-Ser. [0427] In some embodiments, X 8 is Thr. In some embodiments, X 8 is Gln. [0428] In some embodiments, X 8 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -
- X 8 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 8 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 8 is AIB.
- X 8 is Ala.
- X 8 is D-Ala.
- X 8 is PipAla.
- X 8 is Phg. In some embodiments, X 8 is Phg(4-OH). In some embodiments, X 8 is N-Phenethyl-Gly. In some embodiments, X 8 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 8 is N-(4- OMe-Phenethyl)-Gly. In some embodiments, X 8 is Gly. In some embodiments, X 8 is Val. In some embodiments, X 8 is Ile. In some embodiments, X 8 is Leu. In some embodiments, X 8 is D-Leu. In some embodiments, X 8 is Met.
- X 8 is Phe. In some embodiments, X 8 is hPhe. In some embodiments, X 8 is Pro. In some embodiments, X 8 is Tyr. In some embodiments, X 8 is Trp. In some embodiments, X 8 is D-Trp. [0432] In some embodiments, X 8 is Gly or a Gly derivative.
- X 8 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 8 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 8 is Phg, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Phg, wherein the phenyl of X 8 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Phg(4-OH), wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Phg(4-OH), wherein the phenyl of X 8 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is N-Phenethyl-Gly, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is N-Phenethyl-Gly, wherein the phenyl of X 8 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 8 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 8 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Phe, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Phe, wherein the phenyl of X 8 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is hPhe, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is hPhe, wherein the phenyl of X 8 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl
- X 8 is Trp, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Trp, wherein the phenyl of X 8 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is D-Trp, wherein the phenyl of X 8 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is D-Trp, wherein the phenyl of X 8 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 8 is Arg, hArg, hLys, Gln, or PipAla.
- X 9 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0455] In some embodiments, X 9 is an amino acid group comprising a hydrophobic side chain. [0456] In some embodiments, X 9 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 9 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 9 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 9 is AIB.
- X 9 is Ala.
- X 9 is D-Ala.
- X 9 is PipAla.
- X 9 is Phg. In some embodiments, X 9 is Phg(4-OH). In some embodiments, X 9 is N-Phenethyl-Gly. In some embodiments, X 9 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 9 is N-(4- OMe-Phenethyl)-Gly. In some embodiments, X 9 is Gly. In some embodiments, X 9 is Val. In some embodiments, X 9 is Ile. In some embodiments, X 9 is Leu. In some embodiments, X 9 is D-Leu. In some embodiments, X 9 is Met.
- X 9 is Phe. In some embodiments, X 9 is hPhe. In some embodiments, X 9 is Pro. In some embodiments, X 9 is Tyr. In some embodiments, X 9 is Trp. In some embodiments, X 9 is D-Trp. [0461] In some embodiments, X 9 is Gly or a Gly derivative.
- X 9 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 9 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 9 is Phg, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Phg, wherein the phenyl of X 9 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Phg(4-OH), wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Phg(4-OH), wherein the phenyl of X 9 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is N-Phenethyl-Gly, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is N-Phenethyl-Gly, wherein the phenyl of X 9 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 9 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 9 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Phe, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Phe, wherein the phenyl of X 9 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is hPhe, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is hPhe, wherein the phenyl of X 9 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl,
- X 9 is Trp, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Trp, wherein the phenyl of X 9 is substituted with halo, - OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is D-Trp, wherein the phenyl of X 9 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is D-Trp, wherein the phenyl of X 9 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 9 is Leu or Phe;
- X 10 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 10 is an amino acid group comprising a hydrophobic side chain. [0485] In some embodiments, X 10 is a derivative of an amino acid group comprising a hydrophobic side chain. [0486] In some embodiments, X 10 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -
- X 10 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 10 is AIB.
- X 10 is Ala.
- X 10 is D-Ala.
- X 10 is PipAla.
- X 10 is Phg. In some embodiments, X 10 is Phg(4-OH). In some embodiments, X 10 is N-Phenethyl- Gly. In some embodiments, X 10 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 10 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 10 is Gly. In some embodiments, X 10 is Val. In some embodiments, X 10 is Ile. In some embodiments, X 10 is Leu. In some embodiments, X 10 is D-Leu. In some embodiments, X 10 is Met. In some embodiments, X 10 is Phe.
- X 10 is hPhe. In some embodiments, X 10 is Pro. In some embodiments, X 10 is Tyr. In some embodiments, X 10 is Trp. In some embodiments, X 10 is D- Trp. [0490] In some embodiments, X 10 is Gly or a Gly derivative.
- X 10 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 10 is Phg, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Phg, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Phg(4-OH), wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Phg(4-OH), wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is N-Phenethyl-Gly, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is N-Phenethyl-Gly, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Phe, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Phe, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is hPhe, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is hPhe, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Trp, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is Trp, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is D-Trp, wherein the phenyl of X 10 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is D-Trp, wherein the phenyl of X 10 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 10 is D-Leu or Leu.
- X 11 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof, an amino acid group comprising a hydrophobic side chain, or a derivative thereof, or an amino acid group comprising a electrically charged side chain, or a derivative thereof.
- X 11 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 11 is an amino acid group comprising a polar uncharged side chain.
- X 11 is a derivative of an amino acid group comprising a polar uncharged side chain.
- X 11 is an amino acid group comprising an electrically charged side chain, or a derivative thereof. [0518] In some embodiments, X 11 is an amino acid group comprising an electrically charged side chain. [0519] In some embodiments, X 11 is a derivative of an amino acid group comprising an electrically charged side chain. [0520] In some embodiments, X 11 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0521] In some embodiments, X 11 is an amino acid group comprising a hydrophobic side chain. [0522] In some embodiments, X 11 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 11 is CycloGlu, D-Phe, Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)- Gly, Gly, AIB, Ala, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 2 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , - NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6
- X 11 is CycloGlu, D-Phe, Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)- Gly, Gly, AIB, Ala, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 2 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkeny
- X 11 is CycloGlu, D-Phe, Asn, D-Asn, N-Me-Asn, Ser, Thr, Gln, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)- Gly, Gly, AIB, Ala, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 11 is Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, AIB, Ala, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 11 is optionally substituted with halo, -OH, - O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, AIB, Ala, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl- ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, AIB, Ala, Val, Ile, Leu, D-Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp. [0529] In some embodiments, X 11 is AIB. In some embodiments, X 11 is Ala. In some embodiments, X 11 is PipAla. In some embodiments, X 11 is Phg.
- X 11 is Phg(4-OH). In some embodiments, X 11 is N-Phenethyl-Gly. In some embodiments, X 11 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 11 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 11 is Gly. In some embodiments, X 11 is Val. In some embodiments, X 11 is Ile. In some embodiments, X 11 is Leu. In some embodiments, X 11 is D-Leu. In some embodiments, X 11 is Met. In some embodiments, X 11 is Phe.
- X 11 is hPhe. In some embodiments, X 11 is Pro. In some embodiments, X 11 is Tyr. In some embodiments, X 11 is Trp. In some embodiments, X 11 is D-Trp. [0530] In some embodiments, X 11 is Gly or a Gly derivative.
- X 11 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 11 is Phg, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Phg, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Phg(4-OH), wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Phg(4-OH), wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is N-Phenethyl-Gly, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is N-Phenethyl-Gly, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Phe, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Phe, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is hPhe, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is hPhe, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Trp, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is Trp, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is D-Trp, wherein the phenyl of X 11 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is D-Trp, wherein the phenyl of X 11 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 11 is CycloGlu, D-Phe, Gln, D-Trp, or Trp.
- X 12 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0554] In some embodiments, X 12 is an amino acid group comprising a hydrophobic side chain. [0555] In some embodiments, X 12 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 12 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 12 is AIB.
- X 12 is Ala.
- X 12 is D-Ala.
- X 12 is PipAla.
- X 12 is Phg. In some embodiments, X 12 is Phg(4-OH). In some embodiments, X 12 is N-Phenethyl- Gly. In some embodiments, X 12 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 12 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 12 is Gly. In some embodiments, X 12 is Val. In some embodiments, X 12 is Ile. In some embodiments, X 12 is Leu. In some embodiments, X 12 is D-Leu. In some embodiments, X 12 is Met. In some embodiments, X 12 is Phe.
- X 12 is hPhe. In some embodiments, X 12 is Pro. In some embodiments, X 12 is Tyr. In some embodiments, X 12 is Trp. In some embodiments, X 12 is D- Trp. [0560] In some embodiments, X 12 is Gly or a Gly derivative.
- X 12 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 12 is Phg, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Phg, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Phg(4-OH), wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Phg(4-OH), wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is N-Phenethyl-Gly, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is N-Phenethyl-Gly, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Phe, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Phe, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is hPhe, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is hPhe, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Trp, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is Trp, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is D-Trp, wherein the phenyl of X 12 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is D-Trp, wherein the phenyl of X 12 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 12 is AIB, Ala, D-Ala, or Gly.
- X 13 is an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising an electrically side chain, or derivative thereof.
- X 13 is an amino acid group comprising a polar uncharged side chain, or derivative thereof.
- X 13 is an amino acid group comprising a polar uncharged side chain.
- X 13 is a derivative of an amino acid group comprising a polar uncharged side chain.
- X 13 is an amino acid group comprising an electrically side chain, or derivative thereof.
- X 13 is an amino acid group comprising an electrically side chain. [0589] In some embodiments, X 13 is a derivative of an amino acid group comprising an electrically side chain. [0590] In some embodiments, X 13 is Arg, hArg, D-hArg, hArg(Et) 2 , Asp, Glu, His, Hyp(4- OH), Lys, Lys-palm, Asn, D-Asn, N-Me-Asn, Gln, Ser, or Thr. [0591] In some embodiments, X 13 is Arg. In some embodiments, X 13 is hArg. In some embodiments, X 13 is D-hArg.
- X 13 is hArg(Et) 2 . In some embodiments, X 13 is Asp. In some embodiments, X 13 is Glu. In some embodiments, X 13 is His. In some embodiments, X 13 is Hyp(4-OH). In some embodiments, X 13 is Lys. In some embodiments, X 13 is Lys-palm. In some embodiments, X 13 is Asn. In some embodiments, X 13 is D-Asn. In some embodiments, X 13 is N-Me-Asn. In some embodiments, X 13 is Gln. In some embodiments, X 13 is Ser. In some embodiments, X 13 is Thr.
- X 13 is Arg, hArg(Et) 2 , or Ser.
- X 14 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 14 is an amino acid group comprising a hydrophobic side chain.
- X 14 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 14 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 14 is AIB.
- X 14 is Ala.
- X 14 is D-Ala.
- X 14 is PipAla.
- X 14 is Phg. In some embodiments, X 14 is Phg(4-OH). In some embodiments, X 14 is N-Phenethyl- Gly. In some embodiments, X 14 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 14 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 14 is Gly. In some embodiments, X 14 is Val. In some embodiments, X 14 is Ile. In some embodiments, X 14 is Leu. In some embodiments, X 14 is D-Leu. In some embodiments, X 14 is Met. In some embodiments, X 14 is Phe.
- X 14 is hPhe. In some embodiments, X 14 is Pro. In some embodiments, X 14 is Tyr. In some embodiments, X 14 is Trp. In some embodiments, X 14 is D- Trp. [0599] In some embodiments, X 14 is Gly or a Gly derivative.
- X 14 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 14 is Phg, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Phg, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Phg(4-OH), wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Phg(4-OH), wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is N-Phenethyl-Gly, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is N-Phenethyl-Gly, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Phe, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Phe, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is hPhe, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is hPhe, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Trp, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is Trp, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is D-Trp, wherein the phenyl of X 14 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is D-Trp, wherein the phenyl of X 14 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 14 is AIB, Ala, D-Ala, or Gly.
- X 15 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof. [0623] In some embodiments, X 15 is an amino acid group comprising a polar uncharged side chain. [0624] In some embodiments, X 15 is a derivative of an amino acid group comprising a polar uncharged side chain. [0625] In some embodiments, X 15 is Asn, D-Asn, N-Me-Asn, Gln, Ser, or Thr. [0626] In some embodiments, X 15 is Asn. In some embodiments, X 15 is D-Asn. In some embodiments, X 15 is N-Me-Asn.
- X 15 is Gln. In some embodiments, X 15 is Ser. In some embodiments, X 15 is Thr. [0627] In some embodiments, X 15 is Asn or D-Asn. In some embodiments, X 16 is an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a hydrophobic side chain, or a derivative thereof, or an amino acid group comprising a polar uncharged side chain, or a derivative thereof. [0628] In some embodiments, X 16 is an amino acid group comprising an electrically charged side chain, or a derivative thereof. [0629] In some embodiments, X 16 is an amino acid group comprising an electrically charged side chain.
- X 16 is a derivative of an amino acid group comprising an electrically charged side chain.
- X 16 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 16 is an amino acid group comprising a polar uncharged side chain.
- X 16 is a derivative of an amino acid group comprising a polar uncharged side chain.
- X 16 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 16 is an amino acid group comprising a hydrophobic side chain.
- X 16 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 16 is Arg, hArg, D-hArg, hArg(Et)2, Asp, Glu, His, Hyp(4- OH), Lys, hLys, or Lys-palm.
- X 16 is Arg.
- X 16 is hArg.
- X 16 is D-Arg.
- X 16 is hArg(Et) 2 .
- X 16 is Asp.
- X 16 is Glu.
- X 16 is His.
- X 16 is Hyp(4-OH). In some embodiments, X 16 is Lys. In some embodiments, X 16 is hLys. In some embodiments, X 16 is Lys-palm. [0639] In some embodiments, X 16 is His or Hyp(4-OH). [0640] In some embodiments, X 17 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0641] In some embodiments, X 17 is an amino acid group comprising a hydrophobic side chain. [0642] In some embodiments, X 17 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 17 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 17 is AIB.
- X 17 is Ala.
- X 17 is D-Ala.
- X 17 is PipAla.
- X 17 is Phg. In some embodiments, X 17 is Phg(4-OH). In some embodiments, X 17 is N-Phenethyl- Gly. In some embodiments, X 17 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 17 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 17 is Gly. In some embodiments, X 17 is Val. In some embodiments, X 17 is Ile. In some embodiments, X 17 is Leu. In some embodiments, X 17 is D-Leu. In some embodiments, X 17 is Met. In some embodiments, X 17 is Phe.
- X 17 is hPhe. In some embodiments, X 17 is Pro. In some embodiments, X 17 is Tyr. In some embodiments, X 17 is Trp. In some embodiments, X 17 is D- Trp. [0647] In some embodiments, X 17 is Gly or a Gly derivative.
- X 17 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 17 is Phg, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Phg, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Phg(4-OH), wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Phg(4-OH), wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is N-Phenethyl-Gly, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is N-Phenethyl-Gly, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Phe, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Phe, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is hPhe, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is hPhe, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Trp, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Trp, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is D-Trp, wherein the phenyl of X 17 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is D-Trp, wherein the phenyl of X 17 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 17 is Ala or Gly.
- X 18 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 18 is an amino acid group comprising a hydrophobic side chain.
- X 18 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 18 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -
- X 18 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 18 is AIB.
- X 18 is Ala.
- X 18 is D-Ala.
- X 18 is PipAla.
- X 18 is Phg. In some embodiments, X 18 is Phg(4-OH). In some embodiments, X 18 is N-Phenethyl- Gly. In some embodiments, X 18 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 18 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 18 is Gly. In some embodiments, X 18 is Val. In some embodiments, X 18 is Ile. In some embodiments, X 18 is Leu. In some embodiments, X 18 is D-Leu. In some embodiments, X 18 is Met. In some embodiments, X 18 is Phe.
- X 18 is hPhe. In some embodiments, X 18 is Pro. In some embodiments, X 18 is Tyr. In some embodiments, X 18 is Trp. In some embodiments, X 18 is D- Trp. [0677] In some embodiments, X 18 is Gly or a Gly derivative.
- X 18 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 18 is Phg, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Phg, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Phg(4-OH), wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Phg(4-OH), wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is N-Phenethyl-Gly, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is N-Phenethyl-Gly, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Phe, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Phe, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is hPhe, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is hPhe, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Trp, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Trp, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is D-Trp, wherein the phenyl of X 18 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is D-Trp, wherein the phenyl of X 18 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 18 is Ala or Phg.
- X 19 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 19 is an amino acid group comprising a hydrophobic side chain.
- X 19 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 19 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -
- X 19 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 19 is AIB.
- X 19 is Ala.
- X 19 is D-Ala.
- X 19 is PipAla.
- X 19 is Phg. In some embodiments, X 19 is Phg(4-OH). In some embodiments, X 19 is N-Phenethyl- Gly. In some embodiments, X 19 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 19 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 19 is Gly. In some embodiments, X 19 is Val. In some embodiments, X 19 is Ile. In some embodiments, X 19 is Leu. In some embodiments, X 19 is D-Leu. In some embodiments, X 19 is Met. In some embodiments, X 19 is Phe.
- X 19 is hPhe. In some embodiments, X 19 is Pro. In some embodiments, X 19 is Tyr. In some embodiments, X 19 is Trp. In some embodiments, X 19 is D- Trp. [0707] In some embodiments, X 19 is Gly or a Gly derivative.
- X 19 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 19 is Phg, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Phg, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Phg(4-OH), wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Phg(4-OH), wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is N-Phenethyl-Gly, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is N-Phenethyl-Gly, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Phe, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Phe, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is hPhe, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is hPhe, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Trp, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is Trp, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is D-Trp, wherein the phenyl of X 19 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 19 is D-Trp, wherein the phenyl of X 19 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 20 is an amino acid group comprising a hydrophobic side chain.
- X 20 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 20 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2
- X 20 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 20 is AIB.
- X 20 is Ala.
- X 20 is D-Ala.
- X 20 is PipAla.
- X 20 is Phg. In some embodiments, X 20 is Phg(4-OH). In some embodiments, X 20 is N-Phenethyl- Gly. In some embodiments, X 20 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 20 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 20 is Gly. In some embodiments, X 20 is Val. In some embodiments, X 20 is Ile. In some embodiments, X 20 is Leu. In some embodiments, X 20 is D-Leu. In some embodiments, X 20 is Met. In some embodiments, X 20 is Phe.
- X 20 is hPhe. In some embodiments, X 20 is Pro. In some embodiments, X 20 is Tyr. In some embodiments, X 20 is Trp. In some embodiments, X 20 is D- Trp. [0736] In some embodiments, X 20 is Gly or a Gly derivative.
- X 20 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 20 is Phg, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Phg, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Phg(4-OH), wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Phg(4-OH), wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is N-Phenethyl-Gly, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is N-Phenethyl-Gly, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Phe, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Phe, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is hPhe, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is hPhe, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Trp, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is Trp, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is D-Trp, wherein the phenyl of X 20 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 20 is D-Trp, wherein the phenyl of X 20 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof.
- X 21 is an amino acid group comprising a hydrophobic side chain.
- X 21 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 21 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2
- X 21 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N- Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, D- Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp.
- X 21 is AIB.
- X 21 is Ala.
- X 21 is D-Ala.
- X 21 is PipAla.
- X 21 is Phg. In some embodiments, X 21 is Phg(4-OH). In some embodiments, X 21 is N-Phenethyl- Gly. In some embodiments, X 21 is N(naphtha-2-yl-ethyl)-Gly. In some embodiments, X 21 is N-(4-OMe-Phenethyl)-Gly. In some embodiments, X 21 is Gly. In some embodiments, X 21 is Val. In some embodiments, X 21 is Ile. In some embodiments, X 21 is Leu. In some embodiments, X 21 is D-Leu. In some embodiments, X 21 is Met. In some embodiments, X 21 is Phe.
- X 21 is hPhe. In some embodiments, X 21 is Pro. In some embodiments, X 21 is Tyr. In some embodiments, X 21 is Trp. In some embodiments, X 21 is D- Trp. [0765] In some embodiments, X 21 is Gly or a Gly derivative.
- X 21 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Gly, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2- yl-ethyl)-Gly, or N-(4-OMe-Phenethyl)-Gly.
- X 21 is Phg, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Phg, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Phg(4-OH), wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Phg(4-OH), wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is N-Phenethyl-Gly, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 - C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is N-Phenethyl-Gly, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is N(naphtha-2-yl-ethyl)-Gly, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), - N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is N-(4-OMe-Phenethyl)-Gly, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Phe, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Phe, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is hPhe, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is hPhe, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Trp, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is Trp, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is D-Trp, wherein the phenyl of X 21 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 21 is D-Trp, wherein the phenyl of X 21 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 22 is an amino acid group comprising a polar uncharged side chain, or a derivative thereof.
- X 22 is an amino acid group comprising a polar uncharged side chain. [0789] In some embodiments, X 22 is a derivative of an amino acid group comprising a polar uncharged side chain. [0790] In some embodiments, X 22 is Asn, D-Asn, N-Me-Asn, Gln, Ser, or Thr. [0791] In some embodiments, X 22 is Asn. In some embodiments, X 22 is D-Asn. In some embodiments, X 22 is N-Me-Asn. In some embodiments, X 22 is Gln. In some embodiments, X 22 is Ser. In some embodiments, X 22 is Thr.
- X 23 is an amino acid group comprising a hydrophobic side chain, or a derivative thereof. [0793] In some embodiments, X 23 is an amino acid group comprising a hydrophobic side chain. [0794] In some embodiments, X 23 is a derivative of an amino acid group comprising a hydrophobic side chain.
- X 23 is 2-AOC, 2-AHP, ⁇ -Me-NLE, NLE, NVA, Phe, or Phe(3-Br), wherein the phenyl of X 23 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 23 is 2-AOC.
- X 23 is 2-AHP.
- X 23 is ⁇ -Me-NLE. In some embodiments, X 23 is NLE. [0797] In some embodiments, X 23 is NVA. [0798] In some embodiments, X 23 is Phe or a Phe derivative. [0799] In some embodiments, X 23 is Phe.
- X 23 is Phe, wherein the phenyl of X 23 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 23 is Phe, wherein the phenyl of X 23 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 23 is a Phe derivative.
- X 23 is Phe(3-Br).
- X 23 is Phe(3-Br), wherein the phenyl of X 23 is optionally substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
- X 23 is Phe(3-Br), wherein the phenyl of X 23 is substituted with halo, -OH, -O(C 1 -C 6 alkyl), -CN, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , C 1 -C 6 alkyl, C 2 - C 6 alkenyl, or C 2 -C 6 alkynyl.
- the peptide is of SEQ ID NO: 5: (SEQ ID NO: 5), or an isomer, pharmaceutically acceptable salt, or prodrug thereof.
- the peptide is selected from the peptides described in Table 1 and pharmaceutically acceptable salts thereof. [0808] In some embodiments, the peptide is selected from the peptides described in Table 1. In some embodiments, the peptide is a pharmaceutically acceptable salt of any one of the peptides described in Table 1.
- the present disclosure provides a peptide being an isotopic derivative (e.g., isotopically labeled peptide) of any one of the peptides of the Formulae disclosed herein.
- the peptide is an isotopic derivative of any one of the peptides described in Table 1 and prodrugs and pharmaceutically acceptable salts thereof.
- the peptide is an isotopic derivative of any one of the peptides described in Table 1 and pharmaceutically acceptable salts thereof.
- the peptide is an isotopic derivative of any one of prodrugs of the peptides described in Table 1 and pharmaceutically acceptable salts thereof.
- the peptide is an isotopic derivative of any one of the peptide described in Table 1.
- the isotopic derivative can be prepared using any of a variety of art-recognised techniques.
- the isotopic derivative can generally be prepared by carrying out the procedures disclosed in the Examples described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- the isotopic derivative is a deuterium labeled peptide.
- the isotopic derivative is a deuterium labeled peptide of any one of the peptides of the Formulae disclosed herein.
- isotopic derivative refers to a derivative of a peptide in which one or more atoms are isotopically enriched or labelled.
- an isotopic derivative of a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is isotopically enriched with regard to, or labelled with, one or more isotopes as compared to the corresponding peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- the isotopic derivative is enriched with regard to, or labelled with, one or more atoms selected from 2 H, 13 C, 14 C, 15 N, 18 O, 29 Si, 31 P, and 34 S.
- the isotopic derivative is a deuterium labeled peptide (i.e., being enriched with 2 H with regard to one or more atoms thereof).
- the peptide is a 18 F labeled peptide.
- the peptide is a 123 I labeled peptide, a 124 I labeled peptide, a 125 I labeled peptide, a 129 I labeled peptide, a 131 I labeled peptide, a 135 I labeled peptide, or any combination thereof.
- the peptide is a 33 S labeled peptide, a 34 S labeled peptide, a 35 S labeled peptide, a 36 S labeled peptide, or any combination thereof.
- the 18 F, 123 I, 124 I, 125 I, 129 I, 131 I, 135 I, 32 S, 34 S, 35 S, and/or 36 S labeled peptide can be prepared using any of a variety of art-recognised techniques.
- the deuterium labeled peptide can generally be prepared by carrying out the procedures disclosed in the Examples described herein, by substituting a 18 F, 123 I, 124 I, 125 I, 129 I, 131 I, 135 I, 3 S, 34 S, 35 S, and/or 36 S labeled reagent for a non-isotope labeled reagent.
- a peptide of the invention or a pharmaceutically acceptable salt or solvate thereof that contains one or more of the aforementioned 18 F, 123 I, 124 I, 125 I, 129 I, 131 I, 135 I, 32 S, 34 S, 35 S, and 36 S atom(s) is within the scope of the invention.
- substitution with isotope may afford certain therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements.
- the various functional groups and substituents making up the peptides of the SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 are typically chosen such that the molecular weight of the peptide does not exceed 1000 daltons. More usually, the molecular weight of the peptide will be less than 900, for example less than 800, or less than 750, or less than 700, or less than 650 daltons. More conveniently, the molecular weight is less than 600 and, for example, is 550 daltons or less.
- a suitable pharmaceutically acceptable salt of a peptide of the disclosure is, for example, an acid-addition salt of a peptide of the disclosure which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid.
- an inorganic organic acid for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid.
- a suitable pharmaceutically acceptable salt of a peptide of the disclosure which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- an alkali metal salt for example a sodium or potassium salt
- an alkaline earth metal salt for example a calcium or magnesium salt
- an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- peptides disclosed herein may be presented in one particular configuration. Such particular configuration is not to be construed as limiting the disclosure to one or another isomer, tautomer, regioisomer or stereoisomer, nor does it exclude mixtures of isomers, tautomers, regioisomers or stereoisomers.
- the presentation of a peptide herein in a particular configuration intends to encompass, and to refer to, each of the available isomers, tautomers, regioisomers, and stereoisomers of the peptide, or any mixture thereof; while the presentation further intends to refer to the specific configuration of the peptide.
- peptides disclosed herein may be presented without specified configuration (e.g., without specified stereochemistry). Such presentation intends to encompass all available isomers, tautomers, regioisomers, and stereoisomers of the peptide. In some embodiments, the presentation of a peptide herein without specified configuration intends to refer to each of the available isomers, tautomers, regioisomers, and stereoisomers of the peptide, or any mixture thereof.
- the term “isomerism” means peptides that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space.
- stereoisomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture.” [0827] As used herein, the term “chiral centre” refers to a carbon atom bonded to four nonidentical substituents. [0828] As used herein, the term “chiral isomer” means a peptide with at least one chiral centre.
- Peptides with more than one chiral centre may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture.”
- a stereoisomer may be characterised by the absolute configuration (R or S) of that chiral centre.
- Absolute configuration refers to the arrangement in space of the substituents attached to the chiral centre.
- the substituents attached to the chiral centre under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit.1966, 5, 385; errata 511; Cahn et al., Angew.
- the term “geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds or a cycloalkyl linker (e.g., 1,3-cyclobutyl).
- atropic isomers are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques, it has been possible to separate mixtures of two atropic isomers in select cases.
- tautomer is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solutions where tautomerisation is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertible by tautomerisations is called tautomerism. Of the various types of tautomerism that are possible, two are commonly observed.
- An enantiomer can be characterised by the absolute configuration of its asymmetric centre and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarised light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively).
- a chiral peptide can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
- the peptides of this disclosure may possess one or more asymmetric centres; such peptides can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular peptide in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof.
- the methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of “Advanced Organic Chemistry”, 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form.
- peptides of the disclosure may have geometric isomeric centres (E- and Z- isomers). It is to be understood that the present disclosure encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof that possess inflammasome inhibitory activity. [0837] The present disclosure also encompasses peptides of the disclosure as defined herein which comprise one or more isotopic substitutions. [0838] It is to be understood that the peptides of any sequences described herein include the peptides themselves, as well as their salts, and their solvates, if applicable. A salt, for example, can be formed between an anion and a positively charged group (e.g., amino) on a substituted peptide disclosed herein.
- a salt for example, can be formed between an anion and a positively charged group (e.g., amino) on a substituted peptide disclosed herein.
- Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).
- pharmaceutically acceptable anion refers to an anion suitable for forming a pharmaceutically acceptable salt.
- a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a substituted peptide disclosed herein.
- Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion or diethylamine ion.
- the substituted peptides disclosed herein also include those salts containing quaternary nitrogen atoms.
- the peptides of the present disclosure for example, the salts of the peptides, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules.
- Nonlimiting examples of hydrates include monohydrates, dihydrates, etc.
- Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.
- the term “solvate” means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. Some peptides have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H 2 O.
- analog refers to a chemical peptide that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group). Thus, an analog is a peptide that is similar or comparable in function and appearance, but not in structure origin to the reference peptide.
- derivative refers to peptides that have a common core structure and are substituted with various groups as described herein.
- bioisostere refers to a peptide resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms.
- the objective of a bioisosteric replacement is to create a new peptide with similar biological properties to the parent peptide.
- the bioisosteric replacement may be physicochemically or topologically based.
- Examples of carboxylic acid bioisosteres include, but are not limited to, acyl sulfonamides, tetrazoles, sulfonates and phosphonates. See, e.g., Patani and LaVoie, Chem.
- certain peptides of any one of the sequences disclosed herein may exist in solvated as well as unsolvated forms such as, for example, hydrated forms.
- a suitable pharmaceutically acceptable solvate is, for example, a hydrate such as hemi-hydrate, a mono-hydrate, a di-hydrate or a tri-hydrate. It is to be understood that the disclosure encompasses all such solvated forms that possess inflammasome inhibitory activity.
- certain peptides of any one of the sequences disclosed herein may exhibit polymorphism, and that the disclosure encompasses all such forms, or mixtures thereof, which possess inflammasome inhibitory activity.
- crystalline materials may be analysed using conventional techniques such as X-Ray Powder Diffraction analysis, Differential Scanning Calorimetry, Thermal Gravimetric Analysis, Diffuse Reflectance Infrared Fourier Transform (DRIFT) spectroscopy, Near Infrared (NIR) spectroscopy, solution and/or solid state nuclear magnetic resonance spectroscopy.
- DRIFT Diffuse Reflectance Infrared Fourier Transform
- NIR Near Infrared
- solution and/or solid state nuclear magnetic resonance spectroscopy The water content of such crystalline materials may be determined by Karl Fischer analysis.
- Peptides of any one of the sequences disclosed herein may exist in a number of different tautomeric forms and references to peptides of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 include all such forms.
- tautomeric forms include keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro.
- keto enol enolate Peptides of any one of the sequences disclosed herein containing an amine function may also form N-oxides.
- a reference herein to a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 that contains an amine function also includes the N-oxide.
- one or more than one nitrogen atom may be oxidised to form an N-oxide.
- Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.
- N-oxides can be formed by treatment of the corresponding amine with an oxidising agent such as hydrogen peroxide or a peracid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages. More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine peptide is reacted with meta-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.
- mCPBA meta-chloroperoxybenzoic acid
- the peptides of any one of the sequences disclosed herein may be administered in the form of a prodrug which is broken down in the human or animal body to release a peptide of the disclosure.
- a prodrug may be used to alter the physical properties and/or the pharmacokinetic properties of a peptide of the disclosure.
- a prodrug can be formed when the peptide of the disclosure contains a suitable group or substituent to which a property-modifying group can be attached.
- Examples of prodrugs include derivatives containing in vivo cleavable alkyl or acyl substituents at the ester or amide group in any one of the Formulae disclosed herein.
- the present disclosure includes those peptides of any one of the sequences disclosed herein as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a prodrug thereof. Accordingly, the present disclosure includes those peptides of any one of the sequences disclosed herein that are produced by organic synthetic means and also such peptides that are produced in the human or animal body by way of metabolism of a precursor peptide, that is a peptide of any one of the sequences disclosed herein may be a synthetically-produced peptide or a metabolically-produced peptide.
- a suitable pharmaceutically acceptable prodrug of a peptide of any one of the sequences disclosed herein is one that is based on reasonable medical judgment as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.
- Various forms of prodrug have been described, for example in the following documents: a) Methods in Enzymology, Vol.42, p.309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard- Larsen and H.
- Bundgaard Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p.113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, A.C.S. Symposium Series, Volume 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.
- a suitable pharmaceutically acceptable prodrug of a peptide of any one of the sequences disclosed herein that possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof.
- An in vivo cleavable ester or ether of a peptide of any one of the sequences disclosed herein containing a hydroxy group is, for example, a pharmaceutically acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy peptide.
- Suitable pharmaceutically acceptable ester forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters).
- ester forming groups for a hydroxy group include C 1 -C 10 alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, C 1 -C 10 alkoxycarbonyl groups such as ethoxycarbonyl, N,N-(C 1 -C 6 alkyl) 2 carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups.
- C 1 -C 10 alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups
- C 1 -C 10 alkoxycarbonyl groups such as ethoxycarbonyl, N,N-(C 1 -C 6 alkyl) 2 carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups.
- Suitable pharmaceutically acceptable ether forming groups for a hydroxy group include ⁇ -acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.
- a suitable pharmaceutically acceptable prodrug of a peptide of any one of the sequences disclosed herein that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a C 1-4 alkylamine such as methylamine, a (C1-C4 alkyl)2amine such as dimethylamine, N-ethyl-N-methylamine or diethylamine, a C 1 -C 4 alkoxy-C 2 -C 4 alkylamine such as 2-methoxyethylamine, a phenyl-C 1 - C 4 alkylamine such as benzylamine and amino acids such as glycine or an ester thereof.
- an amine such as ammonia
- a C 1-4 alkylamine such as methylamine
- a (C1-C4 alkyl)2amine such as dimethylamine, N-ethyl-N-methylamine or die
- a suitable pharmaceutically acceptable prodrug of a peptide of any one of the sequences disclosed herein that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof.
- Suitable pharmaceutically acceptable amides from an amino group include, for example an amide formed with C 1 -C 10 alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups.
- ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N- dialkylaminomethyl,morpholinomethyl,piperazin-1-ylmethyl and 4-(C 1 -C 4 alkyl)piperazin-1- ylmethyl.
- the in vivo effects of a peptide of any one of the sequences disclosed herein may also be exerted by way of metabolism of a precursor peptide (a prodrug).
- the present disclosure excludes any individual peptides not possessing the biological activity defined herein.
- Methods of Synthesis [0857] In some aspects, the present disclosure provides a method of preparing a peptide of the present disclosure. [0858] In some aspects, the present disclosure provides a method of preparing a peptide, comprising one or more steps as described herein.
- the present disclosure provides a peptide obtainable by, or obtained by, or directly obtained by a method for preparing a peptide as described herein.
- the present disclosure provides an intermediate as described herein, being suitable for use in a method for preparing a peptide as described herein.
- the peptides of the present disclosure can be prepared by any suitable technique known in the art. Particular processes for the preparation of these peptides are described further in the accompanying examples.
- protecting groups see one of the many general texts on the subject, for example, ‘Protective Groups in Organic Synthesis’ by Theodora Green (publisher: John Wiley & Sons).
- Protecting groups may be removed by any convenient method described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule.
- reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
- a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
- the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed by, for example, hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
- a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
- a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
- the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia.
- an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
- a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
- the processes may then further comprise the additional steps of: (i) removing any protecting groups present; (ii) converting the peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 into another peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; (iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and/or (iv) forming a prodrug thereof.
- the resultant peptides of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 can be isolated and purified using techniques well known in the art. [0870] Conveniently, the reaction of the peptides is carried out in the presence of a suitable solvent, which is preferably inert under the respective reaction conditions.
- suitable solvents comprise but are not limited to hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichlorethylene, 1,2- dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentylmethyl ether (CPME), methyl tert-butyl ether (MTBE) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone,
- reaction temperature is suitably between about -100 °C and 300 °C, depending on the reaction step and the conditions used.
- Reaction times are generally in the range between a fraction of a minute and several days, depending on the reactivity of the respective peptides and the respective reaction conditions. Suitable reaction times are readily determinable by methods known in the art, for example reaction monitoring. Based on the reaction temperatures given above, suitable reaction times generally lie in the range between 10 minutes and 48 hours.
- additional peptides of the present disclosure can be readily prepared.
- peptides of the present disclosure are readily accessible by various synthetic routes, some of which are exemplified in the accompanying examples.
- the synthetic route is solid phase peptide synthesis.
- the skilled person will easily recognise which kind of reagents and reactions conditions are to be used and how they are to be applied and adapted in any particular instance – wherever necessary or useful – in order to obtain the peptides of the present disclosure.
- peptides of the present disclosure can readily be synthesised by reacting other peptides of the present disclosure under suitable conditions, for instance, by converting one particular functional group being present in a peptide of the present disclosure, or a suitable precursor molecule thereof, into another one by applying standard synthetic methods, like reduction, oxidation, addition or substitution reactions; those methods are well known to the skilled person.
- suitable protecting groups as well as methods for introducing and removing them are well-known to the person skilled in the art of chemical synthesis and are described, in more detail, in, e.g., P.G.M. Wuts, T.W.
- peptide stapling is utilized in the synthesis of the peptides of the present disclosure. In some embodiments, stapling is carried out by covalently linking the side-chains of two amino acids, thereby forming a peptide macrocycle.
- Biological Assays Peptides designed, selected and/or optimised by methods described above, once produced, can be characterised using a variety of assays known to those skilled in the art to determine whether the peptides have biological activity.
- the molecules can be characterised by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and/or binding specificity.
- high-throughput screening can be used to speed up analysis using such assays. As a result, it can be possible to rapidly screen the molecules described herein for activity, using techniques known in the art. General methodologies for performing high- throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent No.5,763,263. High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.
- in vitro or in vivo biological assays are may be suitable for detecting the effect of the peptides of the present disclosure.
- These in vitro or in vivo biological assays can include, but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and the assays described herein.
- enzymatic activity assays can include, but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and the assays described herein.
- the orexin peptides A and B may be cleaved from a single precursor molecule (prepro-orexin) that is produced exclusively in the lateral hypothalamus. Both orexin peptides bind with similar high affinity to OX2R, but the orexin-1 receptor (OX1R) may be preferentially bound by OXA. Postsynaptic excitation of these G-protein coupled orexin receptors may stimulate the release of monoaminergic and cholinergic neurotransmitters that promote wakefulness and inhibitory neurotransmitters that suppress REM sleep atonia.
- Assays to detect compound interaction or modulation of the human orexin-2 receptor may comprise ligand binding assays, competitive binding/inhibition assays, and/or functional assays that measure the receptor response to the ligand.
- the term “agonist” refers to any molecule that partially or fully initiates, promotes, induces, increases, and/or activates a biological activity of a native polypeptide disclosed herein (e.g., OXR1 or OXR2). Suitable agonist molecules specifically include agonist peptides or peptide fragments, fragments or amino acid sequence variants of native polypeptides, peptides, small organic molecules, etc.
- the measured signal (e.g., fluorescence) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% higher than the signal measured with a negative control under comparable conditions.
- the measured signal (e.g., fluorescence) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% higher than the signal measured with orexin B under comparable conditions.
- the measured signal e.g., fluorescence
- the measured signal is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%
- these methods include, but are not limited to, binding assays such as competitive inhibition assays and calcium release assays. These assays determine the ability of an agonist to bind the polypeptide of interest (e.g., a receptor or ligand, e.g., OXR2) and therefore indicate the ability of the agonist to promote, increase or activate the activity of the polypeptide or receptor.
- Efficacy of an agonist can also be determined using functional assays, such as the ability of an agonist to activate or promote the function of the polypeptide.
- a functional assay may comprise contacting a polypeptide with a candidate agonist molecule and measuring a detectable change in one or more biological activities normally associated with the polypeptide.
- the assays use cells stably expressing either human orexin type 2 or human orexin type 1 receptor.
- the cells are obtained by inserting the Orexin receptor cDNA into pcDNA3.1(+) plasmid vector, identifying clones by G418 drug resistance selection, and/or growing a single clone for OX2R-CHO and OX1R- CHO in bulk.
- the assay is detected using Fluorescent Imaging Plate Reader TETRA (FLIPR TETRA: manufactured by Molecular Devices).
- the agonist activity of the test peptide is calculated assuming that the fluorescence value of the well containing only the dilution buffer is 0 % and the fluorescence value of the well containing 10 nM human orexin B (Tocris) buffer is 100 %.
- the biological assay is described in the Examples herein.
- Pharmaceutical Compositions [0886] In some aspects, the present disclosure provides a pharmaceutical composition comprising a peptide of the present disclosure as an active ingredient.
- the present disclosure provides a pharmaceutical composition comprising at least one peptide of each of the formulae described herein, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients.
- the present disclosure provides a pharmaceutical composition comprising at least one peptide selected from Table 1. [0887]
- the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- the peptides of present disclosure can be formulated for oral administration in forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions.
- the peptides of present disclosure can also be formulated for intravenous (bolus or in- fusion), intraperitoneal, topical, subcutaneous, intramuscular or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.
- the formulation of the present disclosure may be in the form of an aqueous solution comprising an aqueous vehicle.
- the aqueous vehicle component may comprise water and at least one pharmaceutically acceptable excipient.
- suitable acceptable excipients include those selected from the group consisting of a solubility enhancing agent, chelating agent, preservative, tonicity agent, viscosity/suspending agent, buffer, and pH modifying agent, and a mixture thereof. [0890] Any suitable solubility enhancing agent can be used.
- solubility enhancing agent examples include cyclodextrin, such as those selected from the group consisting of hydroxypropyl- ⁇ -cyclodextrin, methyl- ⁇ -cyclodextrin, randomly methylated- ⁇ -cyclodextrin, ethylated- ⁇ -cyclodextrin, triacetyl- ⁇ -cyclodextrin, peracetylated- ⁇ -cyclodextrin, carboxymethyl- ⁇ -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin, 2-hydroxy-3- (trimethylammonio)propyl- ⁇ -cyclodextrin, glucosyl- ⁇ -cyclodextrin, sulfated ⁇ -cyclodextrin (S- ⁇ -CD), maltosyl- ⁇ -cyclodextrin, ⁇ -cyclodextrin sulfobutyl ether, branched- ⁇ -cyclodextrin, hydroxy
- Any suitable chelating agent can be used.
- a suitable chelating agent include those selected from the group consisting of ethylenediaminetetraacetic acid and metal salts thereof, disodium edetate, trisodium edetate, and tetrasodium edetate, and mixtures thereof.
- Any suitable preservative can be used.
- Examples of a preservative include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetyl pyridinium chloride, benzyl bromide, phenylmercury nitrate, phenylmercury acetate, phenylmercury neodecanoate, merthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propylaminopropyl biguanide, and butyl-p-hydroxybenzoate, and sorbic acid, and mixtures thereof.
- quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethon
- the aqueous vehicle may also include a tonicity agent to adjust the tonicity (osmotic pressure).
- the tonicity agent can be selected from the group consisting of a glycol (such as propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, and a mixture thereof.
- the aqueous vehicle may also contain a viscosity/suspending agent.
- Suitable viscosity/suspending agents include those selected from the group consisting of cellulose derivatives, such as methyl cellulose, ethyl cellulose, hydroxyethylcellulose, polyethylene glycols (such as polyethylene glycol 300, polyethylene glycol 400), carboxymethyl cellulose, hydroxypropylmethyl cellulose, and cross-linked acrylic acid polymers (carbomers), such as polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol (Carbopols - such as Carbopol 934, Carbopol 934P, Carbopol 971, Carbopol 974 and Carbopol 974P), and a mixture thereof.
- cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxyethylcellulose
- polyethylene glycols such as polyethylene glycol 300, polyethylene glycol 400
- carboxymethyl cellulose such as polyethylene glycol 300, polyethylene glycol 400
- carboxymethyl cellulose such as polyethylene
- the formulation may contain a pH modifying agent.
- the pH modifying agent is typically a mineral acid or metal hydroxide base, selected from the group of potassium hydroxide, sodium hydroxide, and hydrochloric acid, and mixtures thereof, and preferably sodium hydroxide and/or hydrochloric acid.
- the aqueous vehicle may also contain a buffering agent to stabilise the pH.
- the buffer is selected from the group consisting of a phosphate buffer (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), a borate buffer (such as boric acid, or salts thereof including disodium tetraborate), a citrate buffer (such as citric acid, or salts thereof including sodium citrate), and ⁇ -aminocaproic acid, and mixtures thereof.
- the formulation may further comprise a wetting agent.
- Suitable classes of wetting agents include those selected from the group consisting of polyoxypropylene-polyoxyethylene block copolymers (poloxamers), polyethoxylated ethers of castor oils, polyoxyethylenated sorbitan esters (polysorbates), polymers of oxyethylated octyl phenol (Tyloxapol), polyoxyl 40 stearate, fatty acid glycol esters, fatty acid glyceryl esters, sucrose fatty esters, and polyoxyethylene fatty esters, and mixtures thereof.
- Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets.
- the active peptide can be incorporated with excipients and used in the form of tablets, troches, or capsules.
- Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the peptide in the fluid carrier is applied orally and swished and expectorated or swallowed.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or peptides of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavouring agent such as peppermint, methyl salicylate, orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- composition which comprises a peptide of the disclosure as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.
- compositions of the disclosure may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).
- oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or
- compositions of the disclosure may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
- compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
- An effective amount of a peptide of the present disclosure for use in therapy is an amount sufficient to treat or prevent an inflammasome related condition referred to herein, slow its progression and/or reduce the symptoms associated with the condition.
- An effective amount of a peptide of the present disclosure for use in therapy is an amount sufficient to treat an inflammasome related condition referred to herein, slow its progression and/or reduce the symptoms associated with the condition.
- the size of the dose for therapeutic or prophylactic purposes of a peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.
- Methods of Use [0905]
- the present disclosure provides a method of modulating orexin receptor activity (e.g., in vitro or in vivo), comprising contacting a cell with an effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof.
- the present disclosure provides a method of modulating orexin-2 receptor activity (e.g., in vitro or in vivo), comprising contacting a cell with an effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof.
- the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the disease or disorder is associated with an implicated orexin receptor activity.
- the disease or disorder is a disease or disorder in which orexin receptor activity is implicated.
- the disease or disorder is associated with an implicated orexin- 2 receptor activity.
- the disease or disorder is a disease or disorder in which orexin-2 receptor activity is implicated.
- the disease or disorder is narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia.
- the present disclosure provides a method of treating or preventing narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing narcolepsy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing a hypersomnia disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing a symptom of a rare genetic disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing a mental health disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing a metabolic syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing osteoporosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing cardiac failure in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing coma in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating or preventing a complication in emergence from anesthesia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating narcolepsy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating a hypersomnia disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating a symptom of a rare genetic disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating a mental health disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating a metabolic syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating osteoporosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating cardiac failure in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating coma in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method of treating a complication in emergence from anesthesia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
- the present disclosure provides a method, use, or peptide or pharmaceutical composition for use of the peptide disclosed herein in combination with one or more additional therapy.
- the one or more additional therapy is oral birth control.
- the one or more additional therapy is administered for the treatment of excessive sleepiness.
- the one or more additional therapy is administered for the treatment of comorbid indications.
- the comorbid indication is depression.
- the comorbid indication is a psychiatric disorder.
- the comorbid indication is hypertension.
- the comorbid indication is a metabolic disorder.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in modulating orexin receptor activity (e.g., in vitro or in vivo).
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in modulating orexin-2 receptor activity (e.g., in vitro or in vivo).
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing a disease or disorder disclosed herein.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating a disease or disorder disclosed herein.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing narcolepsy in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing a hypersomnia disorder in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing a neurodegenerative disorder in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing a symptom of a rare genetic disorder in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing a mental health disorder in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing a metabolic syndrome in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing osteoporosis in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing cardiac failure in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing coma in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating or preventing a complication in emergence from anesthesia in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating narcolepsy in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating a hypersomnia disorder in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating a neurodegenerative disorder in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating a symptom of a rare genetic disorder in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating a mental health disorder in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating a metabolic syndrome in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating osteoporosis in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating cardiac failure in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating coma in a subject in need thereof.
- the present disclosure provides a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof for use in treating a complication in emergence from anesthesia in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for modulating orexin activity (e.g., in vitro or in vivo).
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for modulating orexin-2 activity (e.g., in vitro or in vivo).
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating a disease or disorder disclosed herein.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing narcolepsy in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing a hypersomnia disorder in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing a neurodegenerative disorder in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing a symptom of a rare genetic disorder in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing a mental health disorder in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing a metabolic syndrome in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing osteoporosis in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing cardiac failure in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing coma in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating or preventing a complication in emergence from anesthesia in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating narcolepsy in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating a hypersomnia disorder in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating a neurodegenerative disorder in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating a symptom of a rare genetic disorder in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating a mental health disorder in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating a metabolic syndrome in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating osteoporosis in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating cardiac failure in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating coma in a subject in need thereof.
- the present disclosure provides use of a peptide of the present disclosure or an isomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for treating a complication in emergence from anesthesia in a subject in need thereof.
- the present disclosure provides peptides that function as modulators of orexin receptor activity.
- the peptides of the present disclosure are agonists of the orexin receptor.
- the present disclosure provides peptides that function as modulators of orexin-2 receptor activity.
- the peptides of the present disclosure are agonists of the orexin- 2 receptor.
- the modulation of the orexin receptor is activation of the orexin receptor.
- Effectiveness of peptides of the disclosure can be determined by industry-accepted assays/ disease models according to standard practices of elucidating the same as described in the art and are found in the current general knowledge.
- the present disclosure also provides a method of treating a disease or disorder in which orexin receptor activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a peptide, or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition as defined herein.
- the present disclosure also provides a method of treating a disease or disorder in which orexin-2 receptor activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a peptide, or an isomer, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition as defined herein.
- the present disclosure also provides a method for treating a disease or disorder by decreasing excessive sleepiness and/or excessive daytime sleepiness. [1003] In some embodiments, the present disclosure also provides a method for treating a disease or disorder by decreasing excessive sleepiness. [1004] In some embodiments, the present disclosure also provides a method for treating a disease or disorder by decreasing excessive daytime sleepiness. [1005] In some embodiments, the disease or disorder is associated with excessive sleepiness and/or excessive daytime sleepiness.
- the disease or disorder is a primary hypersomnia disorder, neurodegenerative disorder, a symptom of a hypersomnia/neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or emergence from anesthesia.
- the disease or disorder is a primary hypersomnia disorder, neurodegenerative disorder, a symptom of a hypersomnia/neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia.
- the excessive daytime sleepiness is associated with a neurodegenerative disorder.
- the neurodegenerative disorder associated with excessive daytime sleepiness is Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, or multiple sclerosis.
- the disease or disorder is a recurrence of hypersomnia.
- the recurrence of hypersomnia is narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia.
- the disease or disorder is sleep apnea, traumatic brain injury, age-related cognitive dysfunction, or excessive daytime sleepiness.
- excessive daytime sleepingess is associated with sleep apnea, traumatic brain injury, or age-related cognitive dysfunction.
- the disorder is narcolepsy.
- narcolepsy is narcolepsy type 1.
- the narcolepsy is narcolepsy type 2.
- the hypersomnia is a symptom of narcolepsy.
- the disease or disorder is a symptom of narcolepsy.
- a symptom of narcolepsy is excessive daytime sleepiness, cataplexy, sleep paralysis, hypnopompic and hynogogic hallucinations, disturbed nighttime sleep, or inappropriately timed rapid-eye-movement (REM) sleep.
- a symptom of narcolepsy is excessive daytime sleepiness.
- the symptom of narcolepsy is cataplexy.
- cataplexy is pathognomonic of narcolepsy (e.g., narcolepsy type 1)
- a symptom of narcolepsy is sleep paralysis.
- a symptom of narcolepsy is hypnopompic and hynogogic hallucinations.
- a symptom of narcolepsy is disturbed nighttime sleep.
- a symptom of narcolepsy is inappropriately timed rapid-eye- movement (REM) sleep.
- the neurodegenerative disorder is characterized by cataplexy.
- the neurodegenerative disorder is characterized by excessive daytime sleepiness.
- the neurodegenerative disorder is Parkinson’s disease.
- the neurodegenerative disorder is Alzheimer’s disease.
- the neurodegenerative disorder is Huntington’s disease.
- the neurodegenerative disorder is multiple sclerosis.
- the neurodegenerative disorder is a traumatic brain injury.
- the neurodegenerative disorder is sleep apnea.
- the neurodegenerative disorder is age-related cognitive dysfunction.
- the neurodegenerative disorder is a disorder of recurrent hypersomnia.
- a disorder of recurrent hypersomnia is Klein-Levin syndrome, inappropriately timed sleep, (e.g., delayed- or advanced-sleep phase disorder), shift work disorder, or jet lag disorder.
- the disease or disorder is a symptom of a rare genetic disorder.
- a symptom of a rare genetic disorder is abnormal daytime sleepiness.
- a symptom of a rare genetic disorder is excessive daytime sleepiness.
- a symptom of a rare genetic disorder is sleep onset REM periods.
- a symptom of a rare genetic disorder is characterized by cataplexy-like symptoms.
- a rare genetic disorder is Myotonic Dystrophy, ADCA-DN, Coffin-Lowry syndrome, Moebius syndrome, Norrie disease, Niemann-Pick disease type C, or Prader-Willi syndrome.
- the disease or disorder is a mental health disorder.
- the mental health disorder is attention deficit hyperactivity disorder.
- the mental health disorder is attention deficit disorder.
- the disease or disorder is a metabolic syndrome.
- the metabolic syndrome is obesity.
- the disease or disorder is osteoporosis.
- the disease or disorder is cardiac failure.
- the disease or disorder is a coma.
- the disease or disorder is emergence from anesthesia.
- the disease or disorder is a complication in emergence from anesthesia.
- the disease or disorder is narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a neurological disorder, a symptom of a rare genetic disorder, a psychiatric disorder, a mental health disorder, a circadian rhythm disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia.
- the disease or disorder is narcolepsy, idiopathic hypersomnia, or sleep apnea.
- Peptides of the present disclosure, or pharmaceutically acceptable salts thereof may be administered alone as a sole therapy or can be administered in addition with one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
- therapeutic effectiveness may be enhanced by administration of an adjuvant (i.e. by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the individual is enhanced).
- the benefit experienced by an individual may be increased by administering the peptide of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
- another therapeutic agent which also includes a therapeutic regimen
- the peptide of the present disclosure need not be administered via the same route as other therapeutic agents, and may, because of different physical and chemical characteristics, be administered by a different route.
- the peptide of the disclosure may be administered orally to generate and maintain good blood levels thereof, while the other therapeutic agent may be administered intravenously.
- the initial administration may be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician.
- the particular choice of other therapeutic agent will depend upon the diagnosis of the attending physicians and their judgment of the condition of the individual and the appropriate treatment protocol. According to this aspect of the disclosure there is provided a combination for use in the treatment of a disease in which orexin activity is implicated comprising a peptide of the disclosure as defined hereinbefore, or an isomer, pharmaceutically acceptable salt, or prodrug thereof, and another suitable agent.
- a pharmaceutical composition which comprises a peptide of the disclosure, or an isomer, pharmaceutically acceptable salt, or prodrug thereof, in combination with a suitable, in association with a pharmaceutically acceptable diluent or carrier.
- peptides of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 and pharmaceutically acceptable salts thereof are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of modulators of orexin receptor activity in laboratory animals such as dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- peptides of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 and pharmaceutically acceptable salts thereof are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of modulators of orexin-2 receptor activity in laboratory animals such as dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- the peptides with a 20 amino acid sequence have sufficient potency.
- the peptides with a 21 amino acid sequence have sufficient potency.
- the peptides with a 22 amino acid sequence have sufficient potency.
- the peptides with a 23 amino acid sequence have sufficient potency.
- the peptides with a 26 amino acid sequence do not have sufficient potency.
- any of the alternate embodiments of molecules of the present disclosure described herein also apply.
- the peptides of the disclosure or pharmaceutical compositions comprising these peptides may be administered to a subject by any convenient route of administration, whether systemically, peripherally, or topically (i.e., at the site of desired action).
- Routes of administration include, but are not limited to, oral (e.g.
- transdermal including, e.g., by a patch, plaster, etc.
- transmucosal including, e.g., by a patch, plaster, etc.
- intranasal e.g., by nasal spray or powder
- ocular e.g., by eye drops
- pulmonary e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose
- rectal e.g., by suppository or enema
- vaginal e.g., by pessary
- parenteral for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant
- Exemplary Embodiments [1068] Exemplary Embodiment 1.
- a peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 1), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent or an amino acid group comprising a hydrophobic side chain, or a derivative thereof; X 2 is absent, an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof; X 3 is absent, an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising
- Exemplary Embodiment 2 A peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 2), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent or an amino acid group comprising a hydrophobic side chain, or a derivative thereof; X 2 is absent, an amino acid group comprising a polar uncharged side chain, or derivative thereof, or an amino acid group comprising a hydrophobic side chain, or derivative thereof; X 3 is absent, an amino acid group comprising an electrically charged side chain, or a derivative thereof, an amino acid group comprising a polar uncharged side chain, or a derivative thereof, or an amino acid group comprising a hydrophobic side chain, or
- Exemplary Embodiment 3 A peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 3), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent, AIB, Ala, D-Ala, PipAla, Phg, Phg(4-OH), N-Phenethyl-Gly, N(naphtha-2-yl-ethyl)-Gly, N-(4-OMe-Phenethyl)-Gly, Gly, Val, Ile, Leu, Met, Phe, hPhe, Pro, Tyr, Trp, or D-Trp, wherein the phenyl of X 1 is optionally
- Exemplary Embodiment 4 A peptide having a sequence comprising: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 NH 2 (SEQ ID NO: 4), or an isomer, pharmaceutically acceptable salt, or prodrug thereof, wherein X 1 is absent, AIB, Ala, D-Ala, or Gly; X 2 is absent, D-Ser, or Leu; X 3 is absent, CycloLys, D-Ser, Gln, Phe, or Pro; X 4 is AIB, D-Ser, or Gly; X 5 is Arg, D-Ser, or PipAla; X 6 is Ala, AIB, or D-Ser; X 7 is CycloGlu, CycloLys, D-Ser, or G
- Exemplary Embodiment 5 The peptide of any one of the preceeding Exemplary Embodiments, wherein X 1 is absent.
- Exemplary Embodiment 6. The peptide of any one of the preceeding Exemplary Embodiments, wherein X 2 is absent.
- Exemplary Embodiment 7. The peptide of any one of the preceeding Exemplary Embodiments, wherein X 3 is absent.
- Exemplary Embodiment 8. The peptide of any one of the preceeding Exemplary Embodiments, wherein the peptide is an agonist of human orexin type 2 receptor and human orexin type 1 receptor.
- Exemplary Embodiment 14 The peptide of any one of the preceeding Exemplary Embodiments, wherein the peptide comprises a molecular weight of about 2.1 kDa to 2.6 kDa.
- Exemplary Embodiment 15 The peptide of any one of the preceeding Exemplary Embodiments, wherein X 3 and X 7 form an amide bond.
- Exemplary Embodiment 20 The peptide of any one of the preceeding Exemplary Embodiments, wherein the peptide has a E max for hOX2 that ranges from 94.0 to 105.0.
- Exemplary Embodiment 21 The peptide of any one of the preceeding Exemplary Embodiments, wherein the peptide has a pEC 50 for hOX1 that ranges from 7.0 to 11.0.
- Exemplary Embodiment 22 The peptide of any one of the preceeding Exemplary Embodiments, wherein the peptide has a pEC 50 for hOX1 that ranges from 7.0 to 11.0.
- Exemplary Embodiment 23 The peptide of any one of the preceding Exemplary Embodiments, wherein the peptide is selected from the peptides described in Table 1 and pharmaceutically acceptable salts thereof.
- Exemplary Embodiment 24 A peptide obtainable by, or obtained by, a method described herein.
- Exemplary Embodiment 25 A peptide obtainable by, or obtained by, a method described herein.
- a pharmaceutical composition comprising the peptide of any one of the preceding Exemplary Embodiments or an isomer, pharmaceutically acceptable salt, or prodrug thereof, and a pharmaceutically acceptable diluent or carrier.
- Exemplary Embodiment 26 The pharmaceutical composition of any one of the preceding Exemplary Embodiments, wherein the peptide is selected from the peptides described in Table 1.
- Exemplary Embodiment 27 A method of modulating orexin receptor activity, comprising contacting a cell with an effective amount of the peptide of any one of the preceding Exemplary Embodiments; optionally the activity is in vitro or in vivo.
- Exemplary Embodiment 31 Use of the peptide of any one of the preceding Exemplary Embodiments in the manufacture of a medicament for modulating orexin receptor activity.
- Exemplary Embodiment 32 Use of the peptide of any one of the preceding Exemplary Embodiments in the manufacture of a medicament for treating or preventing a disease or disorder.
- Exemplary Embodiment 33 The method, peptide, pharmaceutical composition, or use of any one of the preceding Exemplary Embodiments, wherein the disease or disorder is associated with an implicated orexin receptor.
- Exemplary Embodiment 34 The method, peptide, pharmaceutical composition, or use of any one of the preceding Exemplary Embodiments, wherein the disease or disorder is associated with an implicated orexin-2 receptor.
- Exemplary Embodiment 35 Exemplary Embodiment 35.
- the disease or disorder is narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a neurological disorder, a symptom of a rare genetic disorder, a psychiatric disorder, a mental health disorder, a circadian rhythm disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia.
- the disease or disorder is narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a neurological disorder, a symptom of a rare genetic disorder, a psychiatric disorder, a mental health disorder, a circadian rhythm disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anesthesia.
- the synthetic strategy is based on the Fmoc (9- Fluorenylmethyloxycarbonyl) group for temporary protection of the ⁇ -amino group, in combination with protecting groups such as tert-butyl (-tBu), tert-butyloxycarbonyl (-Boc), trityl (-Trt) groups for temporary protection of the amino acid side chains (see for example E. Atherton and R. C. Sheppard, “The Fluorenylmethoxycarbonyl Amino Protecting Group”, in “The Peptide Analysis, Synthesis, Biology”; Volume 9-“Special Methods in Peptide Synthesis, Part C”, pp.1-38, S. Undenfriend and J.
- the peptides can be synthesized in a stepwise manner on an insoluble polymer support (also referred to as “resin”) starting from the C-terminus of the peptide.
- a synthesis is begun by appending the C-terminal amino acid of the peptide to the resin through formation of an amide or ester linkage. This allows the eventual release of the resulting peptide as a C terminal amide or carboxylic acid, respectively.
- the C-terminal amino acid and all other amino acids used in the synthesis are required to have their ⁇ -amino groups and side chain functionalities (if present) differentially protected such that the ⁇ -amino protecting group may be selectively removed during the synthesis.
- the coupling of an amino acid is performed by activation of its carboxyl group as an active ester and reaction thereof with the unblocked ⁇ - amino group of the N-terminal amino acid appended to the resin.
- the sequence of ⁇ -amino group deprotection and coupling is repeated until the entire peptide sequence is assembled.
- the peptide is then released from the resin with concomitant deprotection of the side chain functionalities, usually in the presence of appropriate scavengers to limit side reactions.
- the resulting peptide is finally purified by reverse phase HPLC.
- General methods for Peptide Synthesis [1108] The general method used for acyclic peptide synthesis is detailed below for Example 1. 1.
- Peptide Nos.2-4, 8-28, 34 and 35 were synthesized and purified using similar procedures to those detailed above for Example 1. For the Examples below, different materials and, or, different coupling agents, and, or, different equivalents of coupling agents were used. The general method used for cyclic peptide synthesis is detailed below for Example 5. 1) Add DMF to the vessel containing Rink amide MBHA Resin (0.2 mmol, 0.5 g, sub: 0.4 mmol/g) and swell for 2 h. 2) Add 20% piperidine/DMF and mix for 30 min. 3) Drain and then wash with DMF for 30 s, 5 times.
- cleavage buffer (95% TFA/2.5% TIS/2.5% H2O) to the flask containing the side chain protected peptide at rt and stir for 3 h. 2. Filter and collect the filtrate. 3. The peptide is precipitated with cold isopropyl ether and centrifuged (3 min at 3000 rpm). 4. Wash with isopropyl ether two additional times. 5. Dry the crude peptide in vacuo for 2 h. 6. The crude peptide was purified by Prep-HPLC (Solvents: A: 0.075% TFA in H 2 O, B: MeCN) to give Example 5 (60.5 mg).
- Peptide Nos.6, 7, and 29 to 33 were synthesized and purified using similar procedures to those detailed above for Example 5. For the Examples below, different materials and, or, different coupling agents, and, or, different equivalents of coupling agents were used. LCMS properties of purified peptides represented by Examples 1-35 Example 2. Orexin Type 2 Receptor Agonist Activity of Exemplary Peptides. [1113] Stable cell line generation. Obtainment of cells stably expressing either human orexin type 2 or human orexin type 1 receptor: to obtain a stable cell line the Orexin receptor cDNA was inserted into pcDNA3.1(+) plasmid vector and clones identified by G418 drug resistance selection.
- assay buffer 1 0.1 % bovine serum albumin (Sigma Aldrich), 20 mM HEPES (Molecular Dimensions), 250 mM probenecid (Sigma Aldrich), 1X Calcium 5 dye (Molecular Devices) in Hank’s balanced salt solution (Invitrogen)
- assay buffer 2 20 mM HEPES, Hank’s balanced salt solution, 0.1 % bovine serum albumin
- test peptide solution (10 ⁇ l) was added using Fluorescent Imaging Plate Reader TETRA (FLIPR TETRA: manufactured by Molecular Devices), a fluorescence value (excitation wavelength 488 nm, measurement wavelength 570 nm) of each well was measured every one second for 2 min, and the agonist activity was determined using the area of the fluorescence value as an indicator of intracellular Ca2+ concentration.
- the agonist activity of the test peptide was calculated assuming that the fluorescence value of the well added with only the dilution buffer was 0 % and the fluorescence value of the well added with 10 nM human orexin A (Tocris) buffer was 100 %.
- agonist activity values EC50 and Emax of each peptide are shown in Table A below. As used herein, Emax indicates the value at 1 ⁇ M concentration when orexin A is converted to a full agonist (maximum value of agonist activity: 100 %).
- Measurement of orexin type 2 receptor agonist activity Chinese hamster ovary (CHO) cells expressing human orexin type 2 receptor (hOX2R) seeded in each well of 384 well black clear bottom plates (BD Flacon) at 10,000 cells per well and cultured for 24 h in an Ham’s F12 (Gibco) medium containing 10% fetal calf serum (Sigma Aldrich) under the conditions of 37oC, 5 % CO2.
- assay buffer 1 0.1 % bovine serum albumin (Sigma Aldrich), 20 mM HEPES (Molecular Dimensions), 250 mM probenecid (Sigma Aldrich), 1X Calcium 5 dye (Molecular Devices) in Hank’s balanced salt solution (Invitrogen)
- assay buffer 2 20 mM HEPES, Hank’s balanced salt solution, 0.1 % bovine serum albumin
- test peptide solution (10 ⁇ l) was added using Fluorescent Imaging Plate Reader TETRA (FLIPR TETRA: manufactured by Molecular Devices), a fluorescence value (excitation wavelength 488 nm, measurement wavelength 570 nm) of each well was measured every one second for 2 min, and the agonist activity was determined using the area of the fluorescence value as an indicator of intracellular Ca2+ concentration.
- the agonist activity of the test peptide was calculated assuming that the fluorescence value of the well added with only the dilution buffer was 0 % and the fluorescence value of the well added with 10 nM human orexin A (Tocris) buffer was 100 %.
- agonist activity values EC50 and Emax of each peptide are shown in Table A below.
- Emax indicates the value at 1 ⁇ M concentration when orexin A is converted to a full agonist (maximum value of agonist activity: 100 %).
- Values of hOX1 and hOX2 pEC50 in Table A are presented in ranges, in which “+” ⁇ 8.0, 8.0 ⁇ “++” ⁇ 9.0, 9.0 ⁇ “+++” ⁇ 10.0, and 10.0 ⁇ “++++”.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente divulgation concerne un peptide ayant une séquence comprenant : X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23NH2 (SEQ ID NO : 1), et leurs isomères, leurs sels pharmaceutiquement acceptables ou leurs promédicaments, leurs procédés d'utilisation et leurs procédés de préparation.
Les peptides divulgués sont utiles pour moduler l'activité du récepteur de l'orexine et peuvent être utilisés dans le traitement de troubles dans lesquels l'activité du récepteur de l'orexine est impliquée, telle que la narcolepsie, un trouble de l'hypersomnie, un trouble neurodégénératif, le symptôme d'un trouble génétique rare, un trouble de la santé mentale, un syndrome métabolique, l'ostéoporose, une insuffisance cardiaque, un coma ou une complication au réveil après anesthésie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263399495P | 2022-08-19 | 2022-08-19 | |
US63/399,495 | 2022-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024040237A1 true WO2024040237A1 (fr) | 2024-02-22 |
Family
ID=88016330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/072499 WO2024040237A1 (fr) | 2022-08-19 | 2023-08-18 | Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024040237A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
WO2017140845A1 (fr) * | 2016-02-18 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polypeptides pour la préparation de conjugués médicamenteux susceptibles de favoriser l'apoptose dans des cellules exprimant un récepteur des orexines |
WO2023017180A1 (fr) * | 2021-08-13 | 2023-02-16 | Orexia Therapeutics Limited | Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine |
-
2023
- 2023-08-18 WO PCT/US2023/072499 patent/WO2024040237A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
WO2017140845A1 (fr) * | 2016-02-18 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polypeptides pour la préparation de conjugués médicamenteux susceptibles de favoriser l'apoptose dans des cellules exprimant un récepteur des orexines |
WO2023017180A1 (fr) * | 2021-08-13 | 2023-02-16 | Orexia Therapeutics Limited | Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine |
Non-Patent Citations (29)
Title |
---|
"Methods in Enzymology", vol. 42, 1985, ACADEMIC PRESS, pages: 309 - 396 |
"Remington: the Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO. |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO. |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 2005, JOHN WILEY AND SONS, INC. |
CAHN ET AL., ANGEW. CHEM. INTER. EDIT., vol. 5, 1966, pages 385 |
CAHN ET AL., ANGEW. CHEM., vol. 78, 1966, pages 413 |
CAHN ET AL., EXPERIENTIA, vol. 12, 1956, pages 81 |
CAHN, J. CHEM. EDUC., vol. 41, 1964, pages 116 |
CAHNINGOLD, J. CHEM. SOC., 1951, pages 612 |
E. ATHERTONR. C. SHEPPARD: "The Fluorenylmethoxycarbonyl Amino Protecting Group'', in ''The Peptide Analysis, Synthesis, Biology", vol. 9, 1987, ACADEMIC PRESS, article "Special Methods in Peptide Synthesis, Part C", pages: 1 - 38 |
FINGL ET AL., THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 1975 |
G. BARANYR. B. MERRIFIELD: "The Peptides: Analysis, Synthesis, Biology", vol. 2, 1980, ACADEMIC PRESS, article "Special Methods in Peptide Synthesis, Part A", pages: 3 - 284 |
GREENE, T.W.WUTS, P.G. M.: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS |
H. BUNDGAARD ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 77, 1988, pages 285 |
H. BUNDGAARD, ADVANCED DRUG DELIVERY REVIEWS, vol. 8, 1992, pages 1 - 38 |
H. BUNDGAARD: "A Textbook of Drug Design and Development", 1991, article "Design and Application of Pro-drugs", pages: 113 - 191 |
J. M. STEWARTJ. D. YOUNG: "Solid-Phase Peptide Synthesis", 1984, PIERCE CHEMICAL CO., pages: 111 |
KARHU LASSE ET AL: "Stapled truncated orexin peptides as orexin receptor agonists", PEPTIDES, vol. 102, 21 February 2018 (2018-02-21), AMSTERDAM, NL, pages 54 - 60, XP093098531, ISSN: 0196-9781, DOI: 10.1016/j.peptides.2018.02.004 * |
L. FIESERM. FIESER: "Fieser and Fieser's Reagents for organic Synthesis", 1994, JOHN WILEY AND SONS |
L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514 |
LANG MANJA ET AL: "Structure-Activity Studies of Orexin A and Orexin B at the Human Orexin 1 and Orexin 2 Receptors Led to Orexin 2 Receptor Selective and Orexin 1 Receptor Preferring Ligands", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 5, 2004, US, pages 1153 - 1160, XP055980754, ISSN: 0022-2623, DOI: 10.1021/jm030982t * |
N. KAKEYA ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 692 |
P.G.M. WUTST.W. GREENE: "Greene's Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS |
PATANILAVOIE, CHEM. REV., vol. 96, 1996, pages 3147 - 3176 |
R. LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS |
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 2000, COLD SPRING HARBOR PRESS |
SHUICHI ASAHI ET AL: "Development of an orexin-2 receptor selective agonist, [Ala 11, d-Leu 15]orexin-B", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 1, 2003, Amsterdam NL, pages 111 - 113, XP055268609, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(02)00851-X * |
SMITH, M. B.MARCH, J.: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2001, JOHN WILEY AND SONS |
T. HIGUCHIV. STELLA: "Pro-Drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11319319B1 (en) | Compounds for inhibiting NLRP3 and uses thereof | |
WO2023017180A1 (fr) | Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine | |
US8030489B2 (en) | Ornithine derivative | |
US20230331720A1 (en) | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists | |
TW201041890A (en) | 3,3'-spiroindolinone derivatives | |
US20230271973A1 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
ES2757570T3 (es) | Derivado de imidazol usado como agente antiviral y uso del mismo en la preparación de un medicamento | |
US20240239744A1 (en) | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives and related uses | |
CA2822453A1 (fr) | Nouveaux morphinanes utiles en tant qu'analgesiques | |
CA3137091A1 (fr) | Derives de n-(phenyl)-indole-3-sulfonamide et composes apparentes en tant que modulateurs de gpr17 pour le traitement de troubles du systeme nerveux central tels que la sclerose e n plaques | |
CN109568321B (zh) | RORγ调节剂 | |
TW201139442A (en) | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes | |
TW201125566A (en) | Antimicrobial compounds and methods of making and using the same | |
TWI555738B (zh) | 苯并噻唑酮化合物 | |
WO2024040237A1 (fr) | Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine | |
CN110177774A (zh) | 作为Caspase抑制剂的联环化合物 | |
JP5673676B2 (ja) | イミダゾ[1,2−a]ピリジン誘導体 | |
WO2024040245A1 (fr) | Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine | |
WO2024015797A1 (fr) | Dérivés peptidiques et leurs utilisations en tant qu'agonistes de l'orexine | |
JP5663743B2 (ja) | モチリン受容体作動活性を有するオキシインドール誘導体 | |
JP2012519153A5 (fr) | ||
US9840465B2 (en) | Antiviral compounds | |
WO2023167865A1 (fr) | Dérivés hétérocycliques bicycliques et utilisations associées | |
ES2642003T3 (es) | Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2 | |
WO2023077977A1 (fr) | Procédé de préparation d'un dérivé de colchicine et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23768442 Country of ref document: EP Kind code of ref document: A1 |